SARS-CoV-2 Tests: Bridging the Gap Between Laboratory Sensors and Clinical Applications

Nikita Toropov‖⊥, Eleanor Osborne‖⊥, Lovleen Tina Joshi†⊥, James Davidson‡⊥, Caitlin Morgan‡, Joseph Page‡, Justin Pepperell‡*, Frank Vollmer‖*

‖University of Exeter, Living Systems Institute, Exeter, EX4 4QD, United Kingdom

† University of Plymouth, Drake Circus, Plymouth PL4 8AA, United Kingdom

‡ Somerset Lung Centre, Musgrove Park Hospital, Parkfield Drive, Taunton, TA1 5DA, United Kingdom

⊥ These authors have contributed equally

* corresponding authors, contact emails: f.vollmer@exeter.ac.uk; Justin.Pepperell@SomersetFT.nhs.uk

ABSTRACT: This review covers emerging biosensors for SARS-CoV-2 detection together with a review of the biochemical and clinical assays that are in use in hospitals and clinical labs. We discuss the gap on bridging current practice of testing laboratories with nucleic acid amplification methods, and the robustness of assays the laboratories seek, and what emerging SARS-CoV-2 sensors have currently addressed in the literature. Together with the established nucleic acid and biochemical tests, we review emerging technology and antibody tests to determine the effectiveness of vaccines on individuals.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported as a novel coronavirus in December 2019 in Wuhan city, Hubei province, China and determined to be the causative pathogen of the pneumonia outbreak first described in Wuhan.[1-3] The disease, designated as coronavirus disease 2019 (COVID-19), typically presents as a respiratory syndrome on a spectrum; from mild upper respiratory tract infection with symptoms of dry cough and fever, through to severe pneumonia, acute respiratory distress syndrome (ARDS) and mortality.[4, 5] Transmission of the virus is predominantly thought to be airborne via aerosol or droplet acquisition when an infected patient talks, coughs or sneezes within close proximity to an uninfected person.[6] As a direct result, the virus has spread rapidly throughout the global population causing the COVID-19 Pandemic; as of February 2021, SARS-COV-2 has caused 114 million cases worldwide of which 2.53 million suffered mortality and 64.3 million recovered.[7] In an infected patient, manifestation of infection can be asymptomatic and thus it can be difficult to diagnose active, transmissible infection.

SARS-CoV-2

SARS-CoV-2 is an enveloped novel beta coronavirus of the Order *Nidovirales* and Family *Coronaviridae*, containing single stranded, positive sense RNA approximately 29.8 kb to 29.9 kb in length.[8, 9] SARS-CoV-2 is supported by a nucleoprotein (N) and surrounded by a structure consisting of envelope small membrane proteins (E), spike glycoproteins (S), and membrane proteins (M),[10] see Figure 1. The virion is spherical and composed of a helical nucleocapsid that is between 60 nm to 140 nm in diameter within a distinctive envelope comprising the glycoprotein spikes (S) that range from 9 nm to 12 nm in length.[11] These spike proteins outside of the virion look like a solar "corona".[9]


Figure 1. Structure of the SARS-CoV-2 virus particle and concept of qRT-PCR tests of a nasal swab.

The family of coronaviruses include those capable of causing severe disease such as SARS-CoV, MERS-CoV and SARS-CoV-2, and those causing mild illness such as HKU1, NL63, OC43 and 229E.[12] SARS-CoV-2 shares 79.6% of its genetic sequence with SARS-CoV,[1] which was responsible for the Severe Acute Respiratory Syndrome (SARS) outbreak in

2003.[13] SARS-CoV-2 has a wider community transmission than previous coronavirus outbreaks, due to higher viral loads in the upper airway, a wider clinical spectrum of disease increasing asymptomatic and presymptomatic viral transmission and enhanced binding capacity of the viral spike protein.[14]

Coronaviruses have genetically adapted and evolved to infect humans through genetic recombination events from animal hosts such as cattle, chickens and, most commonly, bats.[1, 15] Bats are considered to be the main natural reservoir for coronaviruses, and SARS-CoV-2 has 96.2% genetic similarity to bat beta coronaviruses (SARSr-CoV; RaTG13); however, there is still significant debate as to how humans became infected with SARS-COV-2.[16] It is clear that the virus is zoonotic and the first cases were associated with the "wet" Huanan seafood and wildlife market in Wuhan City, China, of which there are considered to be two lineages- "S" and "L"; however, what is not clear is the exact origin or


Figure 2. Summary of the main clinical testing strategies for SARS-CoV-2. (1) The current gold standard test in symptomatic patients is for a nasopharyngeal swab, on which RT-PCR is performed, using 2-3 primers targeting specific SARS-CoV-2 genes. Up to 40 cycles are performed; a lower cycle threshold (C_T) suggests a higher viral load. Cut-offs for a positive result vary between assays, typically 33-35 cycles are the threshold, with results reported as indeterminate if the threshold is reached after a greater number of cycles. (2) In patients presenting during or after the second week of symptoms, antibody testing may be a useful diagnostic tool. Antibody response can be assessed using either lateral flow tests or laboratory based techniques such as ELISA, providing a quantitative result. (3) Antigen testing use immunoassays to detect specific viral antigens. Nasopharyngeal swab samples are placed into the assays reagent. In lateral flow antigen tests, a sample is dropped onto the absorptive pad of the testing cassette and target viral antigens form a sandwich complex with colloidal gold or other labelled antibodies.

source. Many consider the virus to have genetically adapted and jumped the species boundary to infect humans from bats via an intermediate mammalian host.[1, 4, 16, 17]

SARS-CoV-2 mutation. RNA viruses are known to have high mutation rates which arise when they replicate; however, coronaviruses possess an ability to proof read any errors made during replication via a 3' to 5' exoribonuclease.[18] This has, however, not stopped the emergence of genetic variants of SARS- CoV-2 that could increase transmissibility of the virus.[19, 20] There is evidence of increased mortality in patients infected with novel SARS-CoV-2 variants.[21, 22] In response to the spread of the virus, there has been increased emphasis on tracking emergence of variants to generate useful epidemiological data through large scale pathogen genome sequencing.[20] This had proved important in other viral epidemics such as the Ebola outbreak in the Democratic Republic of Congo and influenza, and in the case of SARS-CoV-2, genomic sequencing globally has revealed that the virus has mutated from its original reference strain SARS-CoV-2 Wuhan-Hu-1.[5, 8, 23, 24] Thus, genome sequencing has played a crucial role in aiding epidemiological understanding of SARS-CoV-2 variants and in tackling the disease. One such success story in the area is The Coronavirus Disease 2019 (COVID19) Genomics UK Consortium (COG) that was launched in March 2020 to sequence SARS-CoV-2 in up to 230 000 people with COVID-19 disease.[25] This consortium has already contributed to finding varying lineages of SARS-CoV-2 within the UK, such as the D614G spike mutation, the globally concerning the B.1.1.7 lineage and the variant of concern (VOC2020/1201).[26-28] Moreover, in South Africa, genome sequencing revealed a new SARS-CoV-2 variant B.1.351 which has caused further concern as the rise of such mutations may lead to increased transmissibility and virulence of the virus in the future.[29]

Quantification of SARS-CoV-2 viral load. Infectious viruses such as SARS-CoV-2 are usually quantified by measurement of viral RNA using molecular methods.[30] While this does measure the viral titre, this does not measure the exact number of infectious virions within a given sample.[31] The most accurate method of measuring infectious viral load is through laboratory viral cultivation methods such as plaque assays and tissue culture infectious dose (TCID)50 endpoint dilutions.[32]

Plaque assays are quantitative assays that detect the number of infectious SARS-CoV-2 in a given sample. The assay is conducted via preparation of cell monolayers (cell culture) which are infected with concentrations of the virus in a serial dilution, and the number of plaques formed after infection are counted in Plaque Forming Units (PFU).[33] A plaque is formed when a virus particle infects a host cell, replicates and then lyses the cell, killing it. Plaques become visible after the several replication cycles.[32] The tissue culture infectious dose assays measure the ability of the virus to induce cytopathic effects (CPE) in cell culture after infection. The infection is conducted via serial dilution. TCID50 is the unit of measurement which determines the amount of virus required to induce 50% CPE effects in susceptible cells.[34] Due to lack of laboratory resources in clinical settings however, the majority of viral load quantification is conducted via molecular methods.[35]

SARS-CoV-2 diagnostics. Genomic sequencing and tracking emerging strains of virus yields useful information that can be used to develop new diagnostics and aid treatment and triage of patients with COVID-19 disease. Controlling the pandemic is not limited to high income countries who have been able to afford vaccine rollout and thus a key part of this is ensuring that clinicians and healthcare workers can diagnose such strains rapidly, sensitively and specifically in patients who have active SARS-CoV-2 and transmissible infection.[5] While this is more likely in high income countries, developing a low cost, easy to use diagnostic device that is able to directly detect SARS-CoV-2 at the molecular level for use in low to middle income (LMIC) settings is integral to diagnose patients with COVID-19 disease.[36] The ASSURED (Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-free and Deliverable to end users) criteria for a diagnostics for use in low resource settings should be applied in the context of the COVID-19 Pandemic.[37]

Current SARS-CoV-2 testing predominantly involves two pathways, see Figure 2. Table 1 summarises the key characteristics and limitations of current testing strategies. The first is direct testing of the virus in respiratory samples which can be conducted via viral culture, detection of a protein subunit or via detection and/or amplification of nucleic acids.[38, 39] The second relies on detection of SARS-CoV-2 antibodies.

Real- Time, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is considered the most sensitive and specific assay for detection SARS-CoV-2.[30, 40] The assay will detect the genes that encode the proteins that the virus is composed of, alongside an RNA polymerase RdRp which is RNA-dependent and encoded within a large open reading frame ORFab.[5] Importantly, the viral genomes are contained within the virus capsid and must be released via RNA extraction prior to molecular detection. This is a key step in the detection procedure and can increase the turnaround of results if being used at point of care (POC). However, a recent paper by Alexandersen et al.[5] (2020) found that detection of RNA from clinical samples may not be an appropriate indicator of active infection via RT-PCR as SARS-CoV-2 subgenomic RNAs could be detected from 11 days up to 17 days after initial detection of infection due to evidence of nuclease resistance and RNAs being protected by cellular membranes, which could lead to inconsistent PCR positive results.[5]

The viral load in patients increases within 5-6 days after onset of symptoms, with viral shedding occurring 2-3 days before the onset of symptoms.[4, 41] The exact viral load in infected patients ranges between 641 copies/ml to 1.43×10^{11} copies/ml, and a median of $7 \cdot 99 \times 10^4$ in throat samples and $7 \cdot 52 \times 10^5$ in sputum samples respectively.[42] Thus, specimen collection from the nasopharynx, or an oropharyngeal swab, must be conducted appropriately to capture the virus and subsequently detect it within the limit of detection (LoD) of the assay.[40]

Diagnostic laboratory testing to identify cases rapidly and track community spread are vital tools in gaining control of this current global health emergency. As of 1st Feb 2021, over 1.3 billion tests had been carried out for SARS-CoV-2 (https://www.finddx.org/covid-19/test-tracker/).

Here, we review the current testing used in clinical practice and emerging diagnostic sensor technologies. We discuss the challenges that need to be overcome in order for laboratory sensors to become useful in the clinic and as rapid, accurate and cost-effective (ASSURED) tests that are greatly needed for managing the pandemic.

CLINICAL ASSAYS

Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR). Molecular tests rely on direct detection or amplification of nucleic acids. While the "Gold standard" for SARS-CoV-2 molecular detection is qRT-PCR, other molecular tests for SARS-COV-2 are also being developed and evaluated. Loop mediated isothermal amplification (LAMP) has emerged as a viable alternative to qRT-PCR due its turnaround time from sample to result alongside maintaining its sensitivity and specificity without the use of a thermal cycler.[43] Lamb *et al.* (2020)[44] demonstrated detection of SARS-CoV-2 within 30 minutes using a modified Reverse Transcriptase LAMP assay which could be used at POC if required. Unlike qRT-PCR, the RT-LAMP method relies on a colorimetric readout, a thermal colour change from red to yellow when it is processed at 65℃. This removes the need for more expensive processing equipment, using more simple methods to detect colour change.[45] We also note here the use of colorimetric biosensors in association with nanoparticle interaction which also provides a fast and reliable method of detecting SARS-CoV-2 with a red shift denoting the presence of viral surface proteins.[46]

The RT-LAMP assay was directly compared to qRT-PCR and performed optimally with a lower LoD of 0.08 fg which is equal to 304 viral copies.[44] Lu *et al.* (2020)[47] also developed a RT-LAMP assay platform, named iLACO (isothermal LAMP based method for COVID19) that is able to detect SARS-CoV-2 at a lower limit of 60 copies/ μl in patient samples, and, when compared to samples confirmed by qRT-PCR, demonstrated 97.6% sensitivity. A mismatch-tolerant RT-MALP assay has also been developed to detect SARS-CoV-2 where a high fidelity DNA polymerase is used to remove the mismatched base pairs in the LAMP process.[47] The assay allowed improved accuracy of detection of 30 RNA copies of viral gene *RdRp* within approximately 40 minutes and showed 100% consistency when compared to the standard qRT-PCR assay. Finally, another RT-LAMP assay developed by Zhang *et al.* (2020)[48] demonstrated a LoD of ~120 copies or 4.8 copies per μL, which also shows the sensitivity and specificity of this assay. Thus RT-LAMP assays are a suitable alternative to qRT-PCR assays.

Interestingly, combining RT-LAMP with CRISPR (clustered regularly interspaced short palindromic repeats) technology is another molecular diagnostic method that is gaining traction for detection of SARS-CoV-2. A study by Broughton *et al.* (2020)[49] demonstrated that SARS-CoV-2 could be detected by combining RT-LAMP with CRISPR-Cas12a in a lateral flow assay format within 40 minutes from respiratory swab RNA extracts. This CRISPR-Cas12 DETECTR technology demonstrated similar sensitivity and specificity to qRT-PCR assays, detecting 1 x 10[4] copies/ml; however, an RNA extraction step was required prior to utilisation of the test.[49] CRISPR and Cas proteins identify and break down any foreign nucleic acids encountered by bacteria and archaea, acting as a form of adaptive immunity for

these microorganisms. The degradation of these foreign nucleic acids is mediated via specific RNA molecules which activate the Cas nucleases to cleave any single stranded DNA. Thus, the CRISPR Cas systems can be exploited for use in detection by use of ssDNA reporters that can detect this cleavage and generate a readout.[50] Huang *et al.* (2020)[51] also developed a similar qRT-PCR, CRISPR-Cas12a assay which was able to detect two copies of RNA per sample, which when compared to the qRT-PCR, was unable to detect less than five copies of the RNA target.[51] Guo *et al.* (2020) have also developed an integrated viral nucleic acid detection platform- CASdetect (CRISPR assisted detection) for SARS-CoV-2.[52] The assay utilises Cas12b-mediated DNA detection methods to detect a limit of 1x 10[4] copies/ml of virus without cross reactivity, similar to the previous studies described above. However, interestingly, authors recognise the need to liberate the RNA from the capsid, and thus tested genome spin column extraction kits against lysis buffer kits, finding that lysis buffer kits would be more useful for POC testing (POCT) and spin columns useful for hospitals.[52] Authors also attempted to make the CASdetect more suitable for use at POC by developing a blue light box which could be used to determine the fluorescent signal generated in presence of SARS-CoV-2.

Recently, Ning et al.[53] developed a chip-based CRISPR-Cas12a technique of saliva tests for COVID-19 detection. The system exhibits complete concordance with qRT-PCR results and equipped with a smartphone-based microscopic device that may allow reduction of the infrastructure and expertise required to obtain ultrasensitive diagnostics tools.

POC and lab-on-chip tests. Testing for SARS-CoV-2 within primary care and the community is essential to prevent further community transmission. This requires expansion of current testing capacity, and while this has been achieved somewhat by setting up SARS-CoV-2 testing laboratories,[54] this expansion requires accurate development and implementation of rapid POC tests for SARS-CoV-2. The diagnostic sensitivity of rapid POC molecular tests for SARS-CoV-2 must be comparable to those of Gold standard qRT-PCR tests and have limited steps for ease of use (ASSURED diagnostics).[37] Another key stumbling block for development of such rapid POC tests is the first step of nucleic acid extraction, which can increase the duration of the POC itself. Moreover, high quality clinical specimens are essential to enable detection of the virus in clinical samples.[38]

CovidNudge is an example of a novel, integrated gene detection system that utilises RT-PCR in 90 minutes to detect SARS-CoV-2 without need for laboratory handling, thus negating risk to healthcare workers, and does not require sample pre-processing.[55] The assay is multiplexed to be able to detect 7 viral targets (*rdrp1, rdrp2, e*-gene, *n*-gene and n1, n2, and n3 genes) within a self-contained DnaCartridge that comprises a lab-on-chip device which enables a sample to result PCR reaction. The cartridge contains a staple preparation unit, with all buffers to extract and purify the RNA, and an amplification unit. The CovidNudge test was found to be able to detect SARS-CoV-2 with a specificity of 100%, and a sensitivity of 94% when compared to laboratory-based testing. However, the time taken for testing alongside the need RNA extraction step, despite being integrated, may

not be appropriate for use within a shorter period of time, such as within the time of a general practitioners (GP) appointment (~15 minutes) or when results are required immediately. This is where the majority of molecular POC diagnostics tests fall short.

Lab-on-Chip technologies have also been used to detect SARS-CoV-2 and represent an efficient means of detecting the virus molecularly. Label-free electrochemical detection of SARS-CoV-2 was reported by Rodriguez-Manzano et al.[56] where an ion-sensitive field-effect transistor (ISFET) and was comparable to testing with qRT-PCR; however, while the device was able to detect RNA within 20 minutes, the RNA from the samples had been extracted prior to testing and thus this does not represent a raw sample to result turnaround. Such devices are discussed in more detail in Section 'Virus sensor technologies'.

Other promising POC technologies include use of nucleic acid and aptamer-based biosensors, such as plasmonics and localised surface plasmon resonance to generate detection signals. A good example of this is the use of dual function plasmonic biosensor to detect SARS-CoV-2 within clinical samples, as described by Qui et al. (2020).[57] This biosensor is able to detect viral RNA sequences RdRp, ORF1ab and the E genes from SARS-CoV-2 at a lower LoD of 0.22 pM in a multiplexed assay; the specifics of this device are discussed below. The use of plasmonics and DNA sequences to capture nucleic acid targets from varying microorganisms has been proven prior and represents a highly sensitive, specific and efficient means of molecular detection of pathogens, but also uses microwave energy to liberate nucleic acids from the sample within seconds, rather than relying on other longer nucleic acid extraction methods. A POC device that could generate a highly sensitive and specific result, comparable to qRT-PCR, from raw sample, ideally within 15 minutes, would be immensely useful within the POC testing diagnostic sphere.

Despite the emergence of newer SARS-CoV-2 diagnostics, real time reverse transcription has remained the gold standard worldwide in the diagnosis of COVID-19.[30, 58-62] UK government data showed a total of 63.5 million RT-PCR tests for SARS-CoV-2 had been conducted between April 2020 and January 2021, with daily testing capacity rising thirty-fold during this time, up to 800,000 tests a day, (https://coronavirus.data.gov.uk/details/testing). The process involves reverse transcription of ribonucleic acid (RNA) and amplification of nucleic acid for subsequent analysis (NAATs). Corman et al. was the first team to finalise an international protocol and outline standards associated with the test.[30] They recommended using primers targeting one or several nucleic acids related to SARS-CoV-2.[30, 58] These targets aimed to increase the sensitivity of the test to SARS-CoV-2 and minimise cross-reactivity with other known coronaviruses. The Centre for Disease Control (CDC) assesses for two regions of the viral nucleocapsid gene N1 and N2 and for human RNase P gene (https://www.cdc.gov/). Whereas, the World Health Organisation (WHO) tests for SARS-CoV-2 RNA-dependent RNA polymerase and envelope (E) genes.

The use of multiple primer/probes in the RT-PCR technique means that it is unlikely to be significantly affected by mutations seen in SARS-CoV-2 genetic variants. For example, the TaqPath RT-PCT COVID-19 test uses three primer/probe sets to different genomic regions (Gene Orf-1ab, N protein and S protein), so, unless mutations occur at all three regions, variants are still likely to be detected. Indeed, the change in the signature of the response to one of the 3 primers used helped to raise suspicion of the British variant (B.1.1.7).[63] Once mutated variants are identified RT-PCR tests can be rapidly adapted to include primers sequences to detect the new strain.[64, 65] However, the likelihood of false negatives would be expected to increase with increasing number of mutation sites in techniques targeting fewer genomic regions.

There have been multiple systematic reviews on sample collection; a meta-analysis from Mohammadi et al. concluded that sputum samples were the most sensitive for SARS-CoV-2 detection with nasopharyngeal second and oropharyngeal the least effective.[62] However, given the dry nature of cough and reduced sputum production, the nasopharyngeal swab has become the gold-standard internationally. There have been concerns raised about the false-negative rate of the RT-PCR method with samples from the nasopharynx. Various studies have put its sensitivity between 61 and 70%. These results have been explained by inconsistent sampling methods, a variety of different and sometimes not standardized kits, difficulties in preparation methods and shortages of correct transport medium. RT-PCR testing remains the primary diagnostic test in confirming a diagnosis of COVID-19 in symptomatic individuals presenting to healthcare centers. Limitations in sensitivity results in the requirement for repeated testing in patients with presumed false-negative results when there is a high clinical suspicion for disease and other supporting positive diagnostic features such as typical radiographic changes.

The other unclear variable is viral load. Most studies have concluded that it peaks within the first 2 weeks of infection. There is even less data and analysis of sensitivity in asymptomatic carriers or those with very few respiratory symptoms. This is a concerning pitfall as RT-PCR testing is being used to screen patients attending healthcare centers for elective procedures or with non-COVID related acute presentations. With a high community prevalence of asymptomatic infection and the possibility of transmission prior to symptom onset there will be significant numbers of false-negative tests among this patient cohort leaving vulnerable hospitalized patients at risk of nosocomial infection.

There are also other pitfalls of this method. Despite the rapid emergence of miniturized RT-PCR testing capabilities to aid worldwide use of the test, some countries lack the laboratories and personnel to rely effectively and scale up to this form of mass testing. All of these factors have led to a shift in diagnostics to overcome these shortfalls.

Viral antigen testing. Coronavirus-19 antigens have been shown to be detectable in the serum, urine and mucous membranes of patients with early COVID-19 infection. The presence of antigen, through rapid detection testing (RDT), holds promise as an effective strategy for the early diagnosis and isolation of confirmed cases.[66] Rapid COVID-19 antigen testing operates on the basis of lateral flow to detect viral antigen through immobilised coated COVID-19 antibody. This POC testing is appealing not only for its

speed, but its replicability and low-cost. However, the use of RDT for other viral infections such as Influenza has historically shown variable sensitivity and therefore been extrapolated to concern for rapid antigen testing in the diagnosis of COVID-19.[59] A recent Cochrane review conducted concluded that POC antigen testing for COVID-19 had an average sensitivity and specificity of 56.2% (95% CI, 29.5-79.8%) and 99.5% (95% CI, 98.1-99.1%) respectively.[67] The variability in the sensitivity of POC antigen testing has proven to be operator dependent with lower results attained when testing is performed by non-trained personnel. Peto et al. [68] suggest that further work is required to determine the level of training that non-trained personnel require to achieve optimal test performance. Furthermore, the false negative rates for rapid antigen testing are predominately confounded by the viral load variability during the course of a patient COVID-19 illness.[58, 69] Therefore, it is recommended that centres using large scale POC antigen testing to identify asymptomatic carriers should have all patients with negative results confirmed against COVID-19 RT-PCR to mitigate for potential false negatives,[70] limiting the clinical usefulness of such tests. Published data is lacking on the performance of lateral flow antigen tests in detecting novel strains, although a WHO statement reports no significant impact on performance (https://www.who.int/csr /don/31-december-2020-sars-cov2-variants/en).

Serological testing. Monitoring the humoral immune response to SARS-CoV-2 infection enables the diagnosis of COVID-19 in patients presenting during or after the second week of symptom onset. However, the clinical utility of such a test is limited, when RT-PCR testing is readily available and accessible within the first 5-7 days of symptoms and has a greater positivity rate (see Figure 3).[71] The low sensitivity of antibody testing in the first week of symptom onset means they have no role in early case identification to halt transmission. This reflects that the median time to seroconversion is between 12-13 days.[72] Antibody response remains detectable for about 4.5 months in a sampled healthcare worker population,[73] although symptomatic and more severe infections appears to produce higher antibody titres[74] and a prolonged immune response.[75]

In the subgroup of patients who present in their second week after symptoms onset, a not infrequent occurrence as deterioration requiring hospitalisation is common around 10 days, the adjunct of serological testing to RT-PCR improves diagnostic accuracy in COVID-19 diagnosis.[76]

Antibody testing for SARS-CoV-2 infection includes enzyme-linked immunosorbent assays (ELISA), chemiluminescence immune assays (CLIA) and lateral flow testing. The foundation for innovative diagnostics lists 625 immunoassay tests from 331 different manufacturers. 461 tests have received approval for use in the European Union (CE-IVD) and 42 US Food and Drug Administration (FDA) Emergency Use Authorisation (https://www.finddx.org/covid-19/pipeline). Clinical data assessing the diagnostic characteristics of these tests is available only for the minority[77-82] and in some published data identification of the specific test used has been censored.[83]

Antibody testing typically identifies IgM and IgG antibody to SARS-CoV-2 either separately or in combination, IgM being first level to rise and fall and IgG later to rise but sustains a longer response.[84, 85] Fewer tests use the IgA antibody. The majority of tests identify the antibodies made against the viral nucleocapsid (NC) protein, but antibodies against the spike protein may be more specific due to potential cross-reactivity with other coronaviruses of the NC protein.

A Cochrane review of 54 studies showed that the specificity of the antibody tests was consistently over 98% with similar results for IgA 98.7% (95% CI 97.2-99.4), IgG 99.1 (98.3-99.6) and combined IgA/IgG 98.7% (97.2-99.4). The sensitivity of the tests showed greater variability, the combined IgM/IgG tests performing best at 22-35 days post symptom onset 96.0% (90.6-98.3). POC serological testing had lower sensitivity than laboratory based tests.[86, 87] There are significant limitations in the studies assessing antibody diagnostic test accuracy. Firstly, the majority of these studies were conducted in hospitalised patients and true COVID-19 cases defined based on a positive RT-PCR positive test, risking inclusion of false positives and potentially underestimating test sensitivity.

The major use of antibody testing is in population level studies to assess infection prevalence and the impacts of public health policy,[88-90] thus most antibody tests are being carried out in a non-hospitalised and predominantly asymptomatic population. The characteristics of time to seroconversion and level of antibody response appear to be different between the severe infection hospitalised groups versus an asymptomatic population,[73, 91] which makes the generalisability of the test characteristics assessed from hospitalised and symptomatic patient serum questionable.[92]

Figure 3. The time relationship between viral load, symptoms and positivity on diagnostic tests. The onset of symptoms (day 0) is usually 5 days after infection. At this early stage corresponding to the window or asymptomatic period, the viral load could be below the RT-PCR threshold and the test may give false-negative results. The same is true at the end of the disease, when the patient is recovering. Seroconversion is variable but may be as early as day 5 with a median between day 10-14 in the first week of the disease serological tests are more likely to give false-negative results. The dotted black line in the graph illustrates the sensitivity of the chemiluminescent assay as derived from the data sheet of a commercial test (Abbott Diagnostics, USA). Ig, immunoglobulin; RT-PCR, reverse transcription-PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Reprinted from Reproductive BioMedicine Online, 41(3), La Marca, A. et al., Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays, Copyright (2020), with permission from Elsevier.

Table 1. Current roles for SARS-CoV-2 diagnostic tests, limitations and ideal test characteristics

	Asymptomatic screening	Symptomatic testing	Convalescent testing and prevalence studies
Primary Objective	Identify asymptomatic patients and inform inpatient and community isolation policies to halt viral transmission	Diagnose active COVID infection, inform treatment decisions	Identify infection rates at a population level Assess population at risk of re-infection
Characteristics of an Ideal test	High sensitivity* Rapid turnaround	High sensitivity	High specificity
Main current testing strategy	Rapid POC Antigen testing ± RT-PCR	RT-PCR	Antibody Testing
Time for result	5 – 20 minutes	40 mins – 24 hours (community transport dependent)	Variable : Lateral flow/POC testing 15-20 minutes; blood sample 1 hour – 24+ hours
Limitations of current test	Low diagnostic accuracy	False negatives during incubation phase	Clinical uncertainty regarding future immunity and risk of re-infection

Necessitates RT-PCR if antigen test positive	False positives in convalescent patients

*Sensitivity is the ability of a test to correctly identify people with a disease, a highly sensitive test with a negative test result means a disease can be more confidently ruled out. Specificity is the ability of a test to identify patients with a disease. A highly specific test with a positive result means a patient can be more confidently diagnosed with the disease. Whilst both characteristics are desirable for a diagnostic test, for the individual especially if presenting with acute symptoms a highly sensitive test may be more helpful as the consequences of incorrectly ruling out a diagnosis with a false negative result outweigh those of a false positive result. At a population level where the aim is to accurately identify only those who have or have had a particular disease a more specific test is most desirable.

Most licencing of these tests for emergency use exemption requires a minimum standard of 98% specificity, but one study of 10 lateral flow antibody testing kits identified only 4 of these met this standard.[93] When conducting mass screening of the population, specificity of greater than 98% may still not be sufficient for the test to be useful. The positive predictive value (PPV) of such a test when the prevalence is 10% is estimated at about 80%,[92] one in 5 positive results will be a false positive. Assuming a prevalence similar to that reported by the Office for National Statistics for the population of England, about 2%, the PPV of an antibody test approaches 50% (see UK Office for National Statistics, COVID 19 Infection Survey).

Antibody testing post vaccination. Antibody testing has the potential role of testing vaccine effectiveness; identifying those who may require additional 'booster' doses along with estimating the length of immunity conferred by vaccination. Future SARS-CoV-2 vaccine development and licencing may rely on this approach. However, this remains an area of much uncertainty and ongoing research. The mRNA vaccines (Pfizer-BioNTech[94, 95] and Moderna[96]) and the Oxford/Astra-Zeneca vaccine[97, 98] induce an antibody response to the receptor binding domain of the SARS-CoV-2 spike protein, anti-nucleocapsid (N) protein antibodies are only produced after native SARS-CoV-2 infection[99, 100]. Measurement of the functional effectiveness of the antibody response to vaccination is via a plaque reduction neutralisation technique (PRNT) which is labour intensive, expensive and requires level 3 biosafety as live virus is required.[101] Other surrogate/pseudotyped neutralisation tests have been developed, but remain challenging to deploy on scale.[102] The correlation of quantitative anti-spike protein antibody levels to functional neutralisation tests offers hope that antibody testing could be used reliably to assess vaccine response.[103, 104] Results from a range of 5 quantitative serological assays showed good agreement in identifying those patients with a negative viral neutralisation test (i.e. lacking functional protection post-vaccination), but further standardisation between serological assays and a larger dataset is required before we can reliably interpret these results in a clinically meaningful way.[105] Laboratory based serological testing using ELISA or chemiluminescence immunoassays (CLIA) has been used in the majority of the studies investigating antibody response post-vaccination, the utility of lateral flow tests or other POC modalities remains to be established.

Specimen type. RT-PCR and Viral Antigen testing is most commonly carried out using nasopharyngeal or combined nasal and throat swab specimens. A recent meta-analysis taking nasopharyngeal swabs as the gold standard showed combined nasal and throat swabs had a sensitivity of 97%.[106] Alternative specimen samples using saliva or nasal only swabs showed reduced sensitivities of 85% and 86% respectively, therefore missing 15% of infected cases. Anal swabs and stool samples have also been investigated, detecting viral particles shed into the gastrointestinal (GI) tract.[107] GI specimens have the potential advantage of extending the detection window of infection beyond that of upper airway swabs. However clinically the emergence of antibody testing has thankfully filled this niche.

Current diagnostic testing relies on specimens that are uncomfortable and in some e.g. infants or people living with dementia may be challenging to obtain. Additionally whilst self-testing has become the norm for many people, healthcare worker sampling is superior but incurs additional cost and a personal protective equipment burden. Superior diagnostic performance versus RT-PCR using less invasive samples such as saliva or tongue swabs should be the goal for novel diagnostic technologies if there is to be a paradigm shift in diagnostic pathways.

VIRUS SENSOR TECHNOLOGIES

The COVID-19 pandemic has revealed that novel SARS-CoV-2 sensors and detection methods are urgently needed, especially in developing countries where access to tests performed in clinical laboratories is limited. Factors such as cost, access, healthcare, complexity of assays, assay time and difficulty in collecting the samples makes widespread testing difficult. Electrical, mechanical, and optical biosensors devices can alleviate some of these problems, enabling more rapid and assured assays at a lower cost, with less sample preparation meaning a clinical lab is not required. Biosensor devices are versatile and can be used for POC and home testing. As we show in Table 2, there are many different types of sensors that are useful for detecting virus material and viral particles, with potential for developing much-needed and improved sensing assays for SARS-CoV-2 detection. Recently, efforts have intensified to develop SARS-CoV-2 biosensor devices and to improve upon their accuracy and sensitivity. Current approaches show that it is possible to reduce the time for analysis and achieve a high detection sensitivity on platforms suitable for developing POC applications.

We identify three important steps for developing electrical, optical and mechanical SARS-CoV-2 biosensor devices. The first step is the identification of a suitable biorecognition element, such as an antibody that is able to make a specific molecular interaction with the SARS-CoV-2 target. Examples include virus capsid protein, human angiotensin-converting enzyme 2 (ACE2)[108] and aptamers[109] that target

SARS-CoV-2. The specific biomarker targets for detecting SARS-CoV-2 infection include human immunoglobulins and specific virus proteins such as the SARS-CoV-2 spike protein, which can be important to target mutations such as the D614G mutation.[109] The SARS-CoV-2 RNA genome currently serves as the key target for detecting the virus in most clinical assays that make use of RT-PCR.[110] In general, the analysis of protein samples typically requires a much larger amount of sample as compared to RT-PCR tests of the RNA genome[110].

The second step in SARS-CoV-2 biosensor development is the identification of a suitable linker to immobilise the biorecognition element to the sensor. The biological recognition element has to be immobilised in such a way that the transducer produces a large signal output when the target biomarker/molecule interacts or binds to the bioreceptor. Ideally, bioreceptors are immobilized on the sensor in a stable, oriented and reproducible way to enable a consistent sensor performance. Multiple linkers and various immobilization techniques for biosensors have been used in the past years: streptavidin–biotin interactions, electrodeposition, physisorption, and chemisorption (see e.g.[111]) are some of the examples. These immobilisation techniques can provide dense and accessible monolayers of bioreceptors which are desired for more sensitive detection.

The third step in biosensor development is to optimise the signal readout and the signal analysis methods. Many different types of transducers find use for SARS-CoV-2 detection. They include plasmonic optical transducers such as surface enhanced Raman spectroscopy (SERS) based lateral flow immunoassays (LFIA), mechanical transducers such as quartz crystal microbalances (QCM), and electrical transducers such as nanowire or graphene-based field effect transistors and electrochemical sensors. Various methods are employed to optimise their signals together with computational algorithms for improving the signal-to-noise ratio (SNR) and the LoD.[112] In the next subsections, we review the main optical, electrical, and mechanical virus sensor devices that are currently being investigated and that can be adapted for SARS-CoV-2 detection, before reviewing those sensors that have already been used for SARS-CoV-2 detection in the section "SARS-CoV-2 electrical, mechanical and optical detection technologies".

Electrical sensors. In this subsection, we review a class of sensors which operate by detecting virus biomarkers from changes in their electric characteristics, i.e. through current, conductance, resistance, or impedance measurements. We review the most recent advances in viral sensing, together with the seminal contributions to the field of electrical sensors.

The first electrical transducers reported in 2001[113] made use of conductance changes for real-time sensing of biological and chemical species. They were based on nanowire sensing elements made from silicon. This work set the stage for further developments and applications in this class of nanowire sensors, which is now being explored for SARS-CoV-2 detection.

Silicon-based electrical sensors of viruses. Work by Cui *et al.*[113] introduced the functional principles of how semiconductor nanowire sensors work in biosensing. Semiconductors exposed to different media can change their electrical properties, e.g. via shifts of the valence band away from the Fermi level, resulting in hole depletion and a reduced conductance.[114]

Binding of biomolecules to the surface of a nanowire leads to the depletion or accumulation of carriers in the 'bulk' of the nanowire (versus only the surface region of a planar device). According to,[113] the conductance response of silicon nanowire-based electrical sensors for biotin-streptavidin interaction can reach $\sim 10^{-8}$ Siemens which corresponds to a concentration range down to picomolar. This high sensitivity allows for single-virus detection as we will discuss in the following sections. Also, the small size of a nanowire suggests that dense arrays of sensors could be prepared, facilitating real time, rapid and multiplexed detection of different biomarkers on integrated electrical sensor chips.

Lieber *et al.* used electrical biosensors based on nanowire field-effect transistors for direct and real-time detection of single particles of Influenza A virus.[115] The sensor schematic is shown in Figure 4. The field-effect transistor with a nanowire-based sensing element, 'gate oxide', demonstrated dependence of conductivity upon binding of single Influenza A virus particles. Conductance changes up to -20 nS were observed for single Influenza A virus binding events, producing a step in the conductance time trace easily visible against the noise of a few nS. Virus binding and unbinding events could be clearly observed from downward and upward steps in the conductance trace. To verify the binding/unbinding events, fluorescence imaging of single virus particles was performed in parallel and compared with the real time sensing data, as shown in Figure 4. Results for the specific detection of influenza A virus and avian adenovirus group III were compared, with high selectivity demonstrated by using anti-hemagglutinin receptors for influenza A detection and anti-adenovirus group III antibody for adenovirus detection. The antibodies were covalently attached to the nanowire sensor. For antibody immobilisation, the nanowire device was exposed to an ethanol solution of 3-(trimethoxysilyl)propyl aldehyde, washed and heated. After this step, the two sets of monoclonal antibodies were chemically linked via their amine groups with the aldehyde-terminated nanowire surfaces in a phosphate buffer solution. Device arrays for multiplexed experiments were made in the same way, except that distinct antibody solutions were spotted on different regions of the array.

Figure 4. Nanowire-based detection of single viruses. (Left) Schematic shows two nanowire devices, 1 and 2, where the nanowires are modified with different antibody receptors. Specific binding of a single virus to the receptors on nanowire 2 produces a conductance change characteristic of the surface charge of the virus only in nanowire 2. When the virus unbinds from the surface, the conductance returns to the baseline value. (Right) Single virus binding selectivity. Simultaneous conductance and optical vs. time data recorded from a single nanowire device with a high density of anti-influenza type A antibody. Influenza A solution was added before point 1, and the solution was switched to pure buffer between points 4 and 5 on the plot. The bright-field and fluorescence images corresponding to time points 1-8 are indicated in the conductance data; the viruses appear as red dots in the images. Each image is 6.5 × 6.5 μm.[115] Copyright 2004 National Academy of Sciences.

Table 2. Electrical, mechanical and optical virus sensors perspective for SARS-CoV-2 detection (* marks technologies demonstrated for SARS-CoV-2 detection)

Device	Virus, biomarker, receptor	Sensitivity	Advantages	Disadvantages
Electrical sensors				
Silicon nanowire sensor (Patolsky et al. [115])	Influenza type A - anti-influenza A antibody	Starting from single viral particles	High sensitivity, rapid test (3-20 minutes)	No crucial disadvantages
Silicon nanowire sensor to analyze exhaled breath(Shen et al.[116])	Influenza A (H3N2 and H1N1)	29 virus particles per μL (in 100-fold diluted exhaled breath condensate)	High sensitivity, rapid test (~1 min)	Relatively long specimen preparation
Double etched porous silicon (Gongalsky et al.[117])	Influenza A - no markers used	Low	Reusable, rapid test (>5 min)	Low sensitivity and big volume of specimen required
Electrochemical sensor* (Si MOSFET) (Xian et al.[118])	SARS-CoV-2 - SARS-CoV-2 spike antibody or cTnI antibody	100 fg/mL (7 fM)	High sensitivity, rapid test (within 1 minute)	No crucial disadvantages
Graphene-based field-effect transistor* (Seo et al.[119])	SARS-CoV-2 - SARS-CoV-2 spike antibody	16-16000 pfu/mL for cultured samples; 1:1 × 10^5 (242 copies/mL) for clinical samples	High sensitivity, big dynamic range of viral concentration, rapid test (within 10 minutes)	No crucial disadvantages
Graphene with gold nanoparticles* (Alafeef et al.[120])	SARS-CoV-2 - oligonucleotides (ssDNA) targeting viral nucleocapsid phosphoprotein	231 copies/ μL and LoD 6.9 copies/μL	High sensitivity, rapid test (less than 5 min)	Relatively high cost

Tin-doped WO$_3$/In$_2$O$_3$ nanowire biosensors (Shariati et al.[121])	Hepatitis B - single-strand DNA oligonucleotides	0.1 pM to 10 μM with limit down to 1 fM	Wide dynamic range of detection of viral concentrations, rapid test (within ~1 min)	No crucial disadvantages
Biosensor based on In$_2$O$_3$ (Ishikawa et al.[122])	SARS virus N-protein - antibody mimic proteins	Sub-nanomolar concentrations	High sensitivity, rapid test (~1-10 min)	No crucial disadvantages
Mechanical sensors				
Microgravimetric immunosensor (Owen et al.[123])	Influenza A - anti-influenza A antibodies	4 virus particles/mL	High sensitivity, rapid test (10 min)	No crucial disadvantages
Quartz crystal microbalances (Cooper et al.[124])	Type 1 herpes simplex virus - anti-gD IgG monoclonal antibody	From single virions level to over six orders of magnitude	Fast detection, high sensitivity, wide dynamic range of viral concentration	40 min for specimen incubation
Optical sensors				
1D Photonic crystal (Shafiee et al.[125])	HIV-1 binding to anti-gp120 antibodies	10^5 copies/ml – 10^8 copies/ml	Relatively wide dynamic range	Diffusion limited
Nanoplasmonic biosensor chip* (Huang et al.[126])	SARS-CoV-2 pseudovirus binding to SARS-CoV-2 mAbs (monoclonal antibodies)	370 particles/ml – 10^7 particles/ml	High sensitivity, rapid test (15 min), portable (can use a microplate reader and mobile phone)	No crucial disadvantages
SERS based LFIA with magnetic nanoparticles (Wang et al.[127])	Influenza A H1N1 virus and human adenovirus simultaneously binding to their complementary antibodies	50 and 10 PFU/ml respectively – 10^7 PFU/ml	High sensitivity and wide range of concentrations detected. Simultaneous detection of different viruses possible.	Relatively long test (30 min)
Plasmonic photothermal and localised surface plasmon resonance biosensor* (Qiu et al.[57])	SARS-CoV-2 nucleotide sequences binding to complementary nucleotides	0.22 pM – 1 μM	High sensitivity and wide range of concentrations detected	Relatively sophisticated and skill-demanding methodology
WGM microsphere (Vollmer et al.[128])	Influenza A virions	~10 fM	Rapid test (within 1 min), high sensitivity. Possible detection without specimen special preparation	Slow for detecting low concentrations unless microfluidics integrated

Field-effect transistors, as well as three-electrode potentiometric and amperometric systems, have potentially wide application as sensors for the detection of pathogens because they are compatible with CMOS manufacturing techniques and, therefore, can be potentially integrated with other electronics and in portable devices. Already, this class of sensors has found use in combination with smart-phones for detecting Zika virus.[129] Note that mobile phones are becoming one of the crucial non-pharmaceutical interventions, which have slowed down the epidemic in many settings; an interesting perspective article about the role of mobile phones in fighting the COVID-19 pandemic can be found here.[130]

An important advance towards real-world applications of the nanowire sensor array was made by Shen *et al.*[116] In contrast to,[115] they developed silicon nanowire sensors for influenza A (H3N2 and H1N1) virus in breath samples. This was possible by passing the liquid condensate obtained from exhaled breath onto the nanowires. The breath condensate samples were collected from a total of 19 human subjects with and without flu symptoms. The collection procedure involved the patient breathing through the mouth onto a cold hydrophobic surface for 5 minutes. The collected samples were further diluted for the experiments.

For sample delivery, they used a single channel with an inlet and outlet made of polydimethylsiloxane (PDMS) and covering the entire nanowire sensor area (~4 μm wide).

This breath-analysis sensor demonstrates a high sensitivity for detection down to 29 virus particles per μL of the 100-fold diluted condensate. The approach also demonstrated a high selectivity and accuracy: for 90% of cases, it was observed that samples tested positive or negative in accordance with the gold standard method qRT-PCR that was used as the control. The flu diagnosis with the electrical sensors took 2 orders of magnitude less time as compared to the RT-qPCR method.

Another class of silicon-based electrical sensor for virus detection is based on AC electrical impedance measurements. Influenza virus particles have been detected with double etched porous silicon,[117] as illustrated in Figure 5.

Porous silicon is a promising material for sensing due to its high surface area, which provides high surface/volume ratio for binding of viral particles to specific receptors, together with the tunability of pore morphology which can be important for the sample delivery. Fabrication of porous silicon is accessible with standard methods and mostly done by electrochemical etching.[117] The porous silicon is then covered with metal electrodes for impedance measurements with a vector network analyser. The background conductance of the etched silicon is negligible, while impedance of the whole circuit is mostly governed by capacitance of the etched silicon and this provides enough sensitivity for the direct measurements of viral particle concentrations.


Figure 5. Double-etched porous silicon with gold electrode deposited: cross-section (A) and top view with a H1N1 virus particle (B). (C) Voltage amplitude vs. frequency of the sensor depending on virus concentration. Reproduced from[117]

In experiments with the porous silicon sensors,[117] Influenza virus strain A/PR/8/1934 (H1N1) stock solution, with initial concentration of about 10^7 TCID50 was used, which indicates 50% tissue culture infective dose in 1 ml. The stock solution was diluted in 0.9% NaCl to adjust the concentrations of viruses to 0.1 TCID50, 100 TCID50 and 1000 TCID50. The prepared 1 ml virus suspension was aerosolized with a nebulizer for 5 minutes into a closed volume in which the porous silicon sensors were placed; no biorecognition elements were used. Figure 5c shows voltage dependences on the AC oscillation frequency before and after adsorption of virions at different concentrations. The increase in the capacitance is caused by infiltration of viruses into the porous structure that leads to a shift of resonance frequency to lower values (about 30 MHz change). This sensor showed stable results after only 5 minutes exposure to the viral aerosol. A similar approach has potential for use in coronavirus detection. A simple advantage of this sensor is that it can be reused after washing in ethanol; measurements were reproducible at least 10 times.

Other materials for electrical sensors of viruses. Apart from silicon-based materials, tin-doped WO_3/In_2O_3 nanowires can serve as virus biosensors,[121] having detected hepatitis B virus. For this, single-strand DNA oligonucleotides were covalently immobilized on the sensor to detect the hybridization of complementary DNA in a label-free approach through electrochemical impedance spectral measurements.

The same class of In_2O_3 sensors have been used to detect SARS-CoV virus N-protein.[122] Each of four major proteins (envelope protein, membrane protein, nucleocapsid (N) protein, and spike protein)[131] plays a role in the virus structure and is involved in the mechanism of the replication cy-

cle. Long before the COVID-19 pandemic, authors[122] introduced antibody mimic proteins in *in vitro* selection experiments as a new class of biorecognition element for SARS biomarker N proteins in biosensors based on the In_2O_3 nanowires. Upon binding of N proteins, changes in the electric current were registered. This platform was capable of specifically detecting the N protein at sub-nanomolar concentrations, in the presence of 44 μM bovine serum albumin as a background.

A gold nanoparticle-decorated graphene field-effect transistor has been proposed for the detection of biotinylated macromolecules with ultrahigh sensitivity and specificity.[132] The authors employed an avidin–biotin technology to demonstrate the specific detection of biotinylated proteins and nucleotides in the sub-picomolar range. The graphene/Au nanoparticles were fabricated on a Si substrate. Their sensing performance was characterized by real-time two-terminal electrical current measurement upon injection of the analyte solution into a silicon pool pre-attached onto the electrodes. The sensing capability of the composite was tested with the biotinylated protein A, with sensitivity of ~0.4 pM achieved. By selection of corresponding linkers, this platform could be useful for coronavirus detection as well.

Mechanical sensors – quartz crystal microbalances. A quartz crystal microbalance (QCM) is a label-free technique that has been developed for several decades for biosensing applications. The key component of QCM is a thin quartz crystal that oscillates at a resonant frequency under applied voltage. In response to binding/unbinding events, the QCM frequency is decreased/increased in accordance with the Sauerbrey equation. These frequency changes are proportional to the mass of materials attached to the sensor. QCM

sensors have potential for coronavirus detection with sensitivity down to units of virus particles per mL or nanograms per cm². QCM-D provides an additional characteristic for sensing, namely the rate of dissipation. This characteristic is defined as the rate of oscillation coming to rest when the applied voltage was switched off. Thus, the dissipation rate could provide the rigidity of the materials attached, i.e. soft materials will tend to dissipate oscillations more readily.

Prior to the COVID-19 pandemic, QCM biosensors have been developed for the detection of influenza A (H_3N_2) virus particles.[123] The biosensor consists of a bioreceptor coupled to a QCM transducer that translates a biorecognition event into a measurable frequency-shift signal. Self-assembled monolayers of mercaptoundecanoic acid were formed on QCM gold electrodes to provide a surface amenable for the immobilization of anti-influenza A antibodies by using NHS/EDC coupling chemistry. Influenza A virions were aerosolized; for this, a nebulizer directly connected to a chamber housing the antibody-modified crystal, a so-called immunochip, was used. Upon exposure to the aerosolized virus, the interaction between the antibody and virus led to a change and damping of the oscillation frequency of the QCM sensor. The magnitude of the frequency change was directly related to the virus concentration. The LoD was estimated to be 4 virus particles/ml.

Another example of virus particle detection with QCM has been demonstrated by Cooper *et al.*[124] Type 1 herpes simplex virus was been chosen as the target. The virions were covalently attached to the microbalance surface, then detached by changing the amplitude of the QCM oscillations. Single virions were detected, based on the registration of changes in the frequency of oscillations; however, the surface preparation is a complex multi-stage process. The microbalance surface was coated with a layer of chromium providing high adhesive properties, a thick layer of gold for high conductance, and then a monolayer of mercaptoundecanoic acid to provide free carboxylic acid groups to the solution phase. These groups were converted to reactive N-hydroxysuccinimide esters and coupled to an anti-gD IgG monoclonal antibody to detect the 120 nm herpes simplex virus particle by binding the virus-specific membrane glycoproteins, including glycoprotein D (gD).

Photonic sensors. The field of photonic biosensing has grown rapidly in recent years and presents many opportunities to expand COVID-19 testing rapidly and efficiently. Several biomarkers have been utilised for virus detection including viral genomic material,[57, 133] surface membrane proteins[126, 134] and label-free detection of intact virions[128, 135], the former two of which require a receptor which differentiates viruses and immobilises the target. A wide variety of sensing methods based on the effect of the interaction between target biomarkers and light are discussed, focusing on optical biosensors already proven to detect viruses including SARS-CoV-2 virions. Such methods provide direct, real-time measurements and high levels of sensitivity, as can be seen in Table 2.

Whispering gallery mode and waveguide based sensors. Individual intact viruses can be directly detected using whispering gallery mode (WGM) resonators (WGRs), which are facilitated by the trapping of light from a tuneable laser by total internal reflection at a resonant wavelength in a

spherical microcavity (Figure 6). Analyte binding perturbs the evanescent field of the mode resulting in a resonant wavelength shift. This reactive sensing mechanism has been used to detect the binding of single Influenza A virions to the surface of a WGM silica microsphere resonator with LoD ~10fM, allowing an accurate lower bound estimate of virus mass and radius to be calculated.[128] Influenza A and SARS-CoV-2 virions have similar radii (~100nm); hence, this method holds potential for development in SARS-CoV-2 detection. Such a method has detected virions as small as MS2 virus, with a mass of ~1% of Influenza A through nanoplasmonic hybridisation of the WGM at the microsphere surface. A plasmonic nanoparticle, such as a gold nanoshell, attached to the microresonator equator enhances sensitivity[136] via localised surface plasmon resonance (LSPR). The resonant oscillation of surface conduction electrons stimulated by photons increases electric field intensity, providing enhanced sensitivity within a small detection volume associated with the LSPR hotspot.[57, 136] However, the ability to distinguish between viruses of similar mass, shape and size usually requires functionalization with receptors to provide specificity.

Figure 6. Experimental setup for a microsphere optical cavity, coupled to a tuneable laser using a tapered optical fibre. Label-free detection of single Influenza A virus particles was achieved using this WGM sensor. Inset graph demonstrates a resonant mode as a dip in the transmission spectrum. Single virus particles perturb the WGM resonance wavelength and shift the transmission dip. Figure reproduced from[128]. Copyright (2008) National Academy of Sciences.

Specific sensing using WGRs was demonstrated using thiol-modified nucleotides conjugated to gold nanorods on the surface of a WGM microsphere. The hybridisation kinetics of nucleotides, including base mismatches in octamers, were detected with concentration between 10 – 100 nM.[133] Cysteamine detection with LoD in the 100 attomolar range has been reported, hence WGRs have potential as extremely sensitive photonic sensors.[137] The typical viral load in patient saliva has been reported to average between 10^5-10^6 SARS-CoV-2 virus particles per ml, corresponding to a concentration of ~0.2-2 fM.[138] Currently, WGM based techniques are often diffusion-limited, however the integration of microfluidics using liquid core waveguides[139] has the potential to further lower LoDs and provides a gateway for

transferring this technology into portable devices for POC testing. For example, Dantham et al.[136] utilised microfluidic channels to pump MS2 virus solution through a chamber containing a microsphere, and external referencing optofluidic microbubble resonator systems have been proven effective for specific detection of biomolecules such as D-biotin.[140]

Specificity and speed in detection is of the utmost importance if a sensor is to have potential use in widespread testing in a pandemic. A Mach-Zehnder-type optical waveguide made from sol-gel detected single Influenza A virions with concentration of 100μg/ml within 15 minutes.[141] The device used a single-mode fibre white light source coupled into the waveguide, with output power and wavelength monitored. Anti-H1N1/HA1 antibody was immobilised on one arm of the device, with the other arm left unfunctionalised. When Influenza A virus particles were added to the arm hybridised with antibodies, virus-antibody binding resulted in a refractive index (RI) shift, with resulting power loss and wavelength shift detected by an optical spectrum analyser. Wavelength and power of light passing through the unfunctionalised arm are unaffected, hence providing a reference measurement[141]. Reference measurements are useful to subtract background signals and reduce noise.[140]

U-bent optical fibres are another low-cost, portable method of photonic detection utilising the change in RI resulting from a molecule binding to the sensor. The optical fibre is coupled to an LED or laser, with a spectrometer measuring the output light and subsequent increased absorbance upon molecule binding. The bend in the fibre increases the penetration depth of the evanescent field of light into the analyte, increasing detection sensitivity by an order of magnitude. Gold nanoparticles bound to the fibre surface further enhance sensitivity via the LSPR mechanism.[142] Huang et al.[134] used a similar approach to detect SARS-CoV nucleocapsid protein with LoD 0.1pg/ml. The LSPR electric field enhancement due to an AuNP on the fibre surface enhanced the fluorescence of a fluorophore bound antibody conjugated to the AuNP when excited by a laser beam. Using a low bandpass filter and photodetector, fluorescence intensity was measured when SARS-CoV nucleocapsid protein bound to its complementary antibody.[134] More recently, a plasmonic fiberoptic absorbance biosensor (P-FAB), with a similar design has been developed based on this technique[143] . This low-cost, portable system provides huge potential for point-of-care testing, as proposed by Muragan et al.[144] for COVID-19.

Surface enhanced Raman spectroscopy sensing. Aside from WGR and waveguide-based sensors, other optical mechanisms have proved effective as biosensing platforms. Raman spectroscopy is used to measure molecular vibrations, utilising the inelastic scattering and consequential loss of energy of a visible or IR photon when it interacts with a molecule. Surface Enhanced Raman Spectroscopy (SERS) is a label-free technique that uses the plasmonic resonant oscillation of surface electrons in metallic nanostructures excited by the incident laser beam. This increases the electric field intensity, thus enhancing intensity of the Raman spectrum of molecules adsorbed onto the sensor surface.[135] This technique has been demonstrated many times for virus detection: Shanmukh et al.[135] applied a variety of respiratory viruses to a silver nanorod array, with a 785nm near-

IR laser used for measurements, achieving LoD of 100 PFU/ml for respiratory syncytial virus. The relative intensity of peaks in the SERS spectra enabled the differentiation of influenza strains, with high reproducibility, and without the need for receptors to provide specificity because specific Raman bands arise from biomarkers such as nucleic acids and surface proteins that can identify a virus.[127, 135]

More recently, SERS has been applied to enhance the sensitivity of lateral flow immunoassays (LFIA), as can be seen in Figure 7, with the advantage of highly sensitive and real-time testing. Simultaneous detection of Influenza A H1N1 virus and human adenovirus was achieved using a SERS-based LFIA, with magnetic SERS strips.[127] Unlike traditional SERS, a solution containing both viruses and their complementary antibodies conjugated to magnetic Fe3O4@Ag nanoparticles was prepared, with a magnet used to separate virions bound to their complementary antibodies from the sample solution. Once the virus-antibody-nanoparticle complexes were resuspended in 70μl running buffer, the enriched solution flowed over strips of immobilised antibodies specific to different viruses on the sensor. Viruses bound to their complementary antibodies on the strip surface and the interaction of molecular bonds with IR light produced a SERS spectrum with intensity enhanced by the presence of Fe3O4@Ag nanoparticles. Sensitivity as low as 10 PFU/ml was recorded for Human adenovirus, with simultaneous detection and differentiation of multiple viruses possible.[127] Moreover, a portable SERS multichannel LFIA was also developed by Xiao et al.,[145] with a similar Au nanotag-antibody-antigen-antibody sandwich utilised for SERS enhancement to detect three cancer markers down to 0.01ng/ml concentration. The portability and ease of operation of this device opens avenues for its translation to POC testing.[145] SERS has been proposed for use in PDMS based microfluidic devices that trap viruses, enabling rapid screening of asymptomatic patients,[146] hence it has huge potential in future diagnostics.

Figure 7. (a) Production method for Fe_3O_4@Ag magnetic nanoparticles functionalised with antibodies and (b) diagram of the Magnetic SERS LFIA with strips to detect H1N1 Influenza and Human Adenovirus[127]. A sample SERS spectrum is shown, which would only occur upon viruses bind-

ing to complementary immobilised antibodies. The spectrum intensity is proportional to virus concentration, with large differences in Raman intensity between strips with and without bound virus-antibody-nanoparticle complexes. Reprinted with permission from.[127] Copyright (2019) American Chemical Society.

Photonic crystal based sensors. A variety of periodic arrangements of dielectric materials at the nanoscale, called photonic crystals (PhC), have been successfully utilised for virus sensing. 1D PhC biosensors consist of periodic strips of dielectric material, which reflect a narrow resonant wavelength band when illuminated by a white light source, while other wavelengths pass through the device. This wavelength corresponds to that at which standing waves form in the device.[125] Shafiee *et al.*[125] utilised such a sub-wavelength grating coated in TiO_2 with immobilised anti-gp120 biotinylated antibodies to capture HIV-1 in serum and PBS samples with concentration between 10^5 and 10^8 copies/ml. Each binding event resulted in a resonant wavelength shift due to the virion altering the bulk RI. Similarly, Pal *et al.*[147] used a silicon 2D PhC coated with antibodies to detect Human Papillomavirus virus-like particles in 10% foetal bovine serum, with LoD of 1.5nM. Such 2D PhCs have periodic variation in dielectric constant in 2D, so exhibit a photonic bandgap (PBG). By changing the size of a single hole in the lattice, an optical cavity is created, with a resonant mode within the PBG. When light from a tunable laser source of wavelength ~1.5μm, at which silicon is transparent, illuminates the device, a dip at the resonant wavelength is observed in the transmission spectrum detected by a photodetector; this resonant wavelength shifts upon virus binding. PhCs tend to have smaller mode volumes than WGRs such as microspheres, making them more sensitive to environmental changes; multiple PhCs in series can also be used for reference measurements and multiple virus strain detection on a single device.[147]

The devices in[125, 147] rely on diffusion of viruses to the sensor surface, which inherently increases measurement time, however examples of PhCs with integrated microfluidics have been produced. Yanik et al.[148] developed an optofluidic nanoplasmonic biosensor, which detected viruses including pseudotyped ebola using antibodies immobilised on a nanoplasmonic array, with detection range of 10^6 - 10^9 PFU/ml. Plasmonic nanoholes couple normally incident light to oscillation of surface plasmons at resonant wavelengths and an effect known as extraordinary light transmission results in increased transmission of other wavelengths, minimising noise. Complex optical setups to couple light are not required due to the normal incidence of light. As for other devices, binding of viruses alters local RI, providing measurable red shifts in the resonant wavelength dip in the transmitted light detected using a spectrometer.[148]

Direct imaging. The focus of this section is on direct sensing, however it is also possible to use imaging to detect viruses and antibodies using techniques including fluorescence microscopy[149] and single-particle interferometric imaging.[150] Notably, a technique called plasmonic resonator absorption microscopy been proven for detection of human IgG against SARS-CoV-2 with LoD of 100 pg/ml.[151] A 1D PhC coated with TiO_2 acts as a narrow bandwidth resonant reflector at 625nm when submerged in aqueous media. Formation of a sandwich immunocomplex of COVID-19 IgG bound to antibodies immobilised on an AuNP, with the COVID-19 IgG then binding to spike proteins immobilised on the PhC surface, increases light absorption when the surface plasmon resonant wavelength matched the PhC resonant wavelength. Reflected resonant intensity decreases in the locality of the AuNP, therefore single particles can be observed and counted. Utilising LED illumination and a 2D image sensor allows for portability of the device.[151] Such techniques for antibody detection will become increasingly important for testing vaccination efficacy.

Electrical virus biosensors have demonstrated a number of important advantages: direct instantaneous measurements of virus particles (in real time or within minutes), high-levels of sensitivity down to single virus particles i.e. using small amounts of analytes, chip-scale sizes and compatibility with CMOS technology of integrated circuits.

Mechanical sensors have several advantages over their electrical counterparts, e.g. the authors[124] claimed that sensitivity of such sensors approaches the single virion level, while the ability to detect particles spans over six orders of magnitude. Also, they can be reusable if washed between assays. However, the incubation time for the virus (herpes simplex) was found to be 40 minutes, which is longer in comparison to measurements taken with other sensor systems. In this regard, photonic and plasmonic sensors represent the most powerful instrumentation with exceptional characteristics: rapid real-time tests and highest sensitivity, down to attomolar concentrations.

Whilst all these techniques provide promise for more sensitive and rapid detection methods in the future, they have not yet been translated for SARS-CoV-2 detection specifically. An ever-increasing number of papers are being published upon this however. In the next subsection, we analyse several successful examples of bridging the gap between sensors demonstrated to date and their applications in SARS-CoV-2 sensing.

SARS-CoV-2 electrical, mechanical and optical detection technologies. Last year, graphene for SARS-CoV-2 detection has been shown as a promising material for sensor transducers. Graphene is a two-dimensional sheet of hexagonally arranged carbon atoms. Graphene-based electrical virus sensors have garnered great attention because graphene has exceptional properties: high electric conductivity, high carrier mobility, and large specific area. Thus, graphene could be an alternative e.g. for silicon nanowire based field-effect transistors, providing a potentially better lower concentration response because the whole sheet of graphene is a sensitive element. Graphene-based coronavirus detection was demonstrated by Seo *et al.*[119] They introduced a COVID-19 diagnostic method using graphene based field-effect transistors (Figure 8) and demonstrated the ability to make highly sensitive and instantaneous measurements using small amounts of analyte of SARS-CoV-2 in cultured and clinical samples.

The sensor was fabricated by coating the gate of the transistor made from graphene sheets, with antibodies that were immobilized using 1-pyrenebutyric acid N-hydroxysuccinimide ester (PBASE) and that were specific against

the SARS-CoV-2 spike protein. For this, graphene was transferred to a SiO₂/Si substrate and soaked in 2 mM PBASE in methanol and then rinsed several times with PBS and deionized water. To immobilise the receptor, the device was exposed to 250 µg/mL SARS-CoV-2 spike antibody. Virus infection experiments were performed from African green monkey kidney Vero E6 cells infected with a clinical isolate of SARS-CoV-2, and with clinical samples collected via nasopharyngeal swabs from COVID-19 patients and healthy subjects. All samples were inactivated by heating at 100 °C for 10 min and were stored at −80 °C for further use. The inactivated viral samples were applied to the graphene sensor's surface. The graphene sensor responded to virus concentrations as low as 16 pfu/mL, and the response was linear up to virus concentrations that were 1000-fold larger. The same experiments were carried out using clinical samples. Sensing signals were obtained using nasopharyngeal swab specimens from COVID-19 patients and the signals were clearly differentiable from those obtained from control samples of non-covid subjects. In addition, the sensor responded to patient samples diluted to as much as 1:1 × 10⁵ (242 virus copies/mL). Furthermore, this sensor was specific and able distinguish the SARS-CoV-2 antigen protein from MERS-CoV.

A graphene-based multiplexed, portable, wireless electrochemical platform for ultra-rapid detection of SARS-CoV-2 has been developed in.[152] The platform uses capture antigens and antibodies immobilized on mass-producible, low-cost graphene electrodes. This multiplexed platform tracks the infection progression by diagnosing the stage of the disease, allowing for the identification of individuals who are infectious, vulnerable, and/or immune. Differential pulse voltammetry and open-circuit potential-electrochemical impedance spectroscopy techniques have been employed to electrochemically detect biomarker targets such as the viral antigen nucleocapsid protein, IgM and IgG immunoglobins,


Figure 8. Schematic diagram of COVID-19 field-effect transistor (FET) sensor operation procedure. Graphene is a sensing material, SARS-CoV-2 spike antibody is conjugated onto the graphene sheet via 1-pyrenebutyric acid N-hydroxysuccinimide ester. Reproduced from[119] Copyright (2020) American Chemical Society.

as well as inflammatory biomarker c-reactive protein (CRP) in blood and saliva samples from COVID-19-positive and negative subjects.

A SARS-CoV-2 biosensor using graphene with gold nanoparticles has been developed by Alafeef *et al.*[120] This biosensor uses gold nanoparticles, capped with highly specific antisense oligonucleotides (ssDNA) targeting the RNA of the viral nucleocapsid phosphoprotein N-gene (Figure 9). The

sensing probes were immobilized on a paper-based electrochemical platform. The biosensor coupled with an electrical readout setup selectively detected the presence of SARS-CoV-2 genetic material in Vero cells and clinical samples. The specific RNA–DNA hybridization led to a change in charge and electron mobility on the graphene surface, which resulted in an instant change in sensor output voltage. The thiol-modified ssDNA-capped gold nanoparticles improved the sensitivity of the electrochemical assay. The sensor response has been validated against RNA samples obtained from Vero cells infected with SARS-CoV-2, while SARS-CoV and MERS-CoV RNA has been used as one of the negative controls. This sensor also demonstrated good performance characteristics such as less than 5 min incubation time, a sensitivity of 231 copies/µl, LoD 6.9 copies/µL, and almost 100% accuracy. Notably, the sensor is less affected by the genomic mutations of the virus because the ssDNA-conjugated gold nanoparticles simultaneously target two separate regions of the SARS-CoV-2 RNA sequence.

One other design for an electrical biosensor for COVID-19 related viral testing is an array consisting of eight gold nanoparticles linked to organic ligands.[153] This was integrated with electronic circuitry and an advanced apparatus that collects a 2-3s exhaled breath sample. As the breath passes through the array of nanoparticles, a mixture of COVID-19-related volatile organic compounds reacts with the sensor causing changes in the electrical resistance. This produces a set of electrical resistance signals as a function of time. We do not analyse this method in detail because further validation studies, in differentiating patients with/without COVID-19 and other lung infections, are needed.

Figure 9. Schematic representation of the operation principle envisaged for the COVID-19 electrochemical sensing platform assembled on paper using graphene and ssDNA capped gold nanoparticles as the transducers, wherein step A: the infected samples will be collected from the nasal swab or saliva of the patients under observation; step B: the viral SARS-CoV-2 RNA will be extracted; step C: the viral RNA will be added on top of the graphene-ssDNA-AuNP platform; step D: incubation of 5 min; and step E: the digital electrochemical output will be recorded. Reproduced from.[120] Copyright (2020) American Chemical Society.

Another technology for SARS-CoV-2 detection, quartz crystal microbalances, can be proposed and use the same principle of sensing as was described – the sensor frequency can be changed under attachment of viral particles. For this, the recognition layer should be prepared on the sensor surface. A recent example of a proposal for implementation of

engineered surfaces for SARS-CoV-2 detection was described by Pandey.[154] The author proposed self-assembled monolayers of hydrophobic and negatively charged groups which were intended to provide specific and strong interactions with spike proteins of coronavirus. Based on the biophysical chemistry of the spike protein, mixed COOH and CH_3 groups appear to be the most appropriate for the strong and specific attachment/binding of the spike S1 protein. To improve the specificity, antibodies (anti-spike glycoprotein like immunoglobulin (Ig), camelid heavy-chain antibody (VHH)) can be immobilized on the modified surfaces.

Figure 10. (a) Schematic of the LSPR and PPT biosensor. Gold nanoislands hybridised with nucleotides are irradiated by two sources for thermoplasmonic heating and plasmonic sensing, enabling detection of complementary nucleotide binding. Reproduced with permission from[57] (https://pubs.acs.org/doi/10.1021/acsnano.0c02439). (b) Nanoplasmonic sensing chip hybridised with SARS-CoV-2 monoclonal antibodies, to which a SARS-CoV-2 virion can bind, in itself bound to ACE2 protein conjugated to AuNPs for plasmonic enhancement.[126] A cartridge containing such a chip for POC testing is shown, alongside a graph of relative optical density change demonstrating the wide range of concentrations this device can detect. Reprinted from Biosensors and Bioelectronics, 171, Huang, L. et al., One-step rapid quantification of SARS-CoV-2 virus particles via low-cost nanoplasmonic sensors in generic microplate reader and POC device, 112685, Copyright (2021), with permission from Elsevier.

Optical biosensors based on surface plasmon resonance phenomenon have been used to detect a variety of respiratory viruses including SARS-CoV using genetic material as a biomarker.[155] Crucially, Qiu et al.[57] presented a plasmonic photothermal (PPT) and localised surface plasmon resonance (LSPR) biosensor shown in Figure 10a, capable of detecting SARS-CoV-2 nucleotide sequences at concentrations of 0.22pM. In addition to the enhanced

sensing capability enabled by LSPR discussed previously, PPT facilitates distinction between two oligonucleotides differing by a few base pairs, enabling distinction between selected SARS-CoV and SARS-CoV-2 sequences. When gold nanoislands functionalised with complementary nucleotides were irradiated by a 532nm laser, hot electrons were generated whose energy dissipated rapidly as heat via the thermoplasmonic effect. Nucleic acid strands have a melting temperature T_m, at which the DNA hybridised strands dissociate. Strands that are complementary have a higher T_m than those which differ by a few base pairs. Thus, the temperature increase produced by PPT means nucleotides with base pair sequence differing from the receptor nucleotide refrained from binding.[57] This provides the potential for use distinguishing the mutant SARS-CoV-2 strains already discussed. However, conventional SPR equipment can be expensive and difficult to transport, making widespread POC use difficult, although it still has potential for lab based processing of tests.

Another design, for a nanoplasmonic biosensor chip, has been used to detect SARS-CoV-2 pseudovirus with concentration as low as 370vp/ml (vp= virus particles)[126] as shown in Figure 10b. A silicon plasmonic nanocup array chip coated with titanium and gold was produced, with SARS-CoV-2 monoclonal antibodies immobilised on the surface. AuNPs labelled with ACE2 protein were bound to SARS-CoV-2 virions, which subsequently bound to immobilised antibodies on the chip. In principle, the chip works as a label free LSPR and photonic crystal biosensor with extraordinary optical transmission providing high sensitivity to local RI changes. Coupling between AuNPs and nanoplasmonic substrate enabled low concentration measurements with enhanced optical signal intensity. A generic microplate reader at 640nm wavelength was used to detect the change in resonant wavelength with virus binding via transmission measurements, as shown in Figure 10b. This makes for a far simpler design than Qiu.[57] Measurements could be taken in 15 minutes and processed using a smartphone connected to a POC device, providing easily transportable, low cost, rapid detection which could be advantageous in resource-limited environments.[126] Moreover, Yoo et al.[156] recently produced a reusable SPR biosensor chip, which uses magnetic particles as a solid substrate for SPR. Once a sensing measurement is complete, a magnet removes these particles. This enables the device to be reused, with H1N1 influenza virus nucleoprotein detected more than 7 times without significant changes in signal. Such a technique has the potential to reduce the cost of SPR technology,[156] allowing widespread use in clinical settings.

The first steps towards devices for SARS-CoV-2 new generation sensing have already been taken. One example of biosensor hardware has been described by Xian *et al.*[118] They proposed a low-cost COVID-19 electrochemical sensor based on a Si metal-oxide-silicon field-effect transistor (MOSFET). As an example, the authors report detection of 100 fg/mL (7 fM) SARS-CoV-2 spike protein in saliva. They have succeeded in making use of a disposable sensor fabricated in-house for COVID-19 detection alongside a Si MOSFET based sensor unit. Notably, electrochemical sensors exploiting potentiometry, voltammetry, coulometry, and electrochemical impedance spectroscopy have great potential for coronavirus detection via coronavirus-related proteins and detection of viral DNA.[157]

DISCUSSION

In the clinic, the standard assay used to identify an active infection of SARS-CoV-2 is a quantitative RT-PCR test. qRT-PCR LoD range between 60 and 300 viral copies per ml. qRT-PCR sensitivity is adequate for detecting most cases when the patient is infectious to others where one encounters a median viral load of 8×10^4 copies/ml. However, qRT-PCR tests encounter a window of false negatives early in the infection cycle when the viral load is low, and also later in the infection cycle when the virus may no longer persist in the upper airway. Overall, the success of a qRT-PCR test in detecting a positive SARS-CoV-2 case in the clinic is about 60%, leading to repeat testing to confirm cases if clinical suspicion for disease is high.

qRT-PCR false positives are often seen in patients who continue to shed viral RNA although viable viral particles cannot be cultured. Viral shedding usually occurs after COVID symptom onset with the obvious exception of asymptomatic patients. It is normal for this to occur for a mean of 17 days after infection, but continues in some patients for several weeks. This can cause confusion as one obtains technically 'correct' positive test results, but these patients do not need to be isolated.[13] False negatives – anecdotally repeating 3 or 4 qRT-PCR tests in cases where clinical suspicion was high for a positive result - were not uncommon during the initial outbreak. These appear less common now as staff perhaps became more familiar with sampling, qRT-PCR tests improved by using multiple primers etc. and our understanding of the time course of viral shedding has progressed. Evidence published early in the COVID-19 pandemic seems to support this with 30-60% positive results from RT-PCR in patients with suspected COVID-19. qRT-PCR seems to offer the most flexible testing platform that could adapt to mutant strains – although adaptable over weeks/months timeframe – otherwise whole gene sequencing is required.

Molecular sensor tests identifying viable viral particles could overcome the problem of persistent positive results. Also, sensors could offer the multiplexed detection of mutants or one could offer specialised kits/sensors devices for each mutant. SPR and PPT devices[57] that detect specified nucleotide sequences using nucleotide hybridisation have the potential for mutant strain detection focussed on certain nucleotide sequences. However, SPR devices will most likely be used in a lab environment, rather than POC application. In future, if different treatments or differences in

prognosis become apparent between mutant strains, a testing platform to differentiate and quantify the presence of viral strains in real time would be an invaluable clinical tool. High sensitivities for the detection of viral particles were already demonstrated with photonic devices, down to 10s-100s PFU/ml.[126, 127]

A qRT-PCR replacement sensor test would need to offer faster turnaround times to enable the more rapid and repetitive testing that will be needed. Less invasive sampling by using saliva or even breath samples instead of the nasopharyngeal swab which is uncomfortable could improve sensor test uptake in and outside the clinic. Rapid sensor tests should ideally match or exceed the current LoD of qRT-PCR to enable the early detection of infection and the detection of infection in prolonged and asymptomatic cases. A number of photonic devices show promise for achieving this. They are potential candidates for replacing laboratory qRT-PCR tests, especially at the point of care, see table 2. Already, optical sensor devices can provide extremely low limits of detection (nanoplasmonic devices achieve 370 particles/ml, graphene based devices achieve 242 virus copies/ml), fast run time (many photonic based sensors operate within 15-30 minutes on site), and a high dynamic range of detection (aM to µM). Plasmonic devices seem most promising for achieving high portability. The nanoplasmonic biosensor chip[126] requires only a point-of-care microplate reader and a smartphone to perform testing.

Lateral flow viral antigen tests currently lack diagnostic accuracy to be single test in a diagnostic pathway. Lateral flow serology tests have only limited clinical value because they identify cases only after risk of infectious transmission. The result of these tests is highly dependent on the developed immunity and the length of the immune response. The often high rate of false positive (and negative) test results needs to be addressed. Laboratory based serological tests have similar issues to lateral flow tests, but improved diagnostic accuracy and there is supporting evidence that they have benefits in public health.[158]

Developing novel sensor-based lateral flow test devices to check the effectiveness of vaccines could become extremely useful. However, more evidence is needed that such tests can identify spike protein antibodies which seem to correlate best with viral neutralising studies. Here, more clarity is needed from the manufacturers of the lateral flow tests on validation data. Lateral flow tests and other POC tests can have a rapid turnaround and would be ideal antigen tests. Most lateral flow tests have a lower sensitivity, suggesting that improvement on the scale of orders of magnitude in LoD is needed for many of the devices to become deployed in the clinic. The currently high LoD together with a limited specificity of these tests means that they are not yet fit for purpose.

Other sensor techniques that directly detect virus particles could become important. Already, SERS lateral flow immune assay with magnetic nanoparticles have demonstrated LoD 50 PFU/ml and 10 PFU/ml for influenza and adenovirus respectively.[127] The intensity of the output spectrum is proportional to viral load, so identification of early stage infection may be possible. These sensors could be used to identify positive cases in the incubation period and could open potential for even more successful treatment pathways. The sensors would allow drugs preventing viral

entry into cells to become of use at the early stage of the infection in similar way to post-exposure prophylaxis in HIV infection.

Private healthcare companies are charging £65 for an antibody test and £125 for a qRT-PCR test. The cost of a lateral flow antibody test is approx. $5 USD (e.g. BinaxNOW COVID-19 Ag Card). Ideally, to ensure future ASSURED sensing throughout the world, we need more affordable tests, with the potential for free tests to be made available in third world countries. Sensor approaches such as reusable SPR chip[156] with magnetic nanoparticles that can be removed after each measurement could help reduce cost of using SPR for POC, with chips useable for different target viruses. Fortunately, antibodies are robust and can be stored at 2-30°C, and are stable for use at room temperature 15-30°C, so portability of sensors can be high.

A key challenge in developing *in vitro* novel diagnostics tests, especially at POC, is adoption of the technologies by stakeholders such as the National Health Service (NHS) in the UK or by the Food and Drug Administration in the USA. For UK adoption, the Medicines and Healthcare products Regulatory Agency and the National Institute for Health and Care Excellence must be informed of the technologies, with the aim of the *in vitro* diagnostic device (IVD) being externally validated to determine whether it meets appropriate sensitivity and specificity. This includes meeting the minimum requirements of the positive predictive value - an essential measurement of diagnostic capability and negative predictive value tested against an appropriate patient population to achieve regulatory conformity and expedite NHS adoption of the technology. The time taken for IVD adoption within the NHS has been approximately 10 years (https://www.bivda.org.uk/).

For the CE Marking to Directive 98/79/EC on in vitro diagnostic medical devices, contact with the MHRA is required for the Registration of the Device and accessories and then to move towards adoption via the Health Technologies Adoption Programme (HTAP), now coordinated by NICE. Assessing the Technology Readiness levels (TRL) of the IVD from 1 to 9 is of importance throughout before use in clinical practice and commercial translation, which also requires commercial partners and a business plan for implementation. Significant funding is also required to achieve commercial translation in order to reach TRL9.

Clinical necessity has driven rapid development of diagnostic testing for SARS-CoV-2. However, what we have seen has been rapid upscaling and adaptation of existing technologies rather than a diagnostic revolution. It is understandable that with timelines in adopting novel diagnostic technologies historically averaging 10 years, research and development funding has focused on established diagnostics rather than novel sensor technologies.

There is much optimism but uncertainty as to the impact of vaccination programs on the SARS-CoV-2 pandemic. Further outbreaks and possible seasonal waves are anticipated, and as such there may be an ongoing need and sufficient time for sensor diagnostics to develop to be ready to be integrated into clinical testing pathways. However after the initial surge to establish testing pathways and investment in infrastructure we may see a fatigue and inertia to innovation with the status quo viewed as adequate. Indeed existing RT-PCR techniques sets a high bar to overcome with high diagnostic accuracy, increasingly rapid turnaround times, scalability, falling costs and detection at low viral loads. Sensor diagnostics will need to offer a paradigm shift or fulfill a critical niche to supplant molecular or immunoassay testing. Examples of such niches are: in patients with suspected false positive RT-PCR tests during their convalescence; rapid testing for mass screening e.g. crowds; testing using less invasive specimens; and to identify patients with or at risk of persistent COVID-19 symptoms ("post COVID-syndrome"). Further enhancing the uptake of sensor-based COVID-19 screening methods may require the introduction of assays that are higher-throughput, especially when compared to RT-PCR. A typical strategy here is to adapt fabrication methods for sensors in array format and finding ways for integrating them with suitable high-throughput microfluidics.

Vocabulary section

Coronaviruses, the family of viruses that can cause illness in humans and animals, seven different types have been found to infect people, including SARS-CoV-2 responsible for the COVID-19 pandemic; COVID-19, the contagious disease caused by SARS-CoV-2; SARS-CoV-2, the severe acute respiratory syndrome coronavirus 2; PCR, the polymerase chain reaction, used to rapidly synthesize copies of a specific DNA, allowing to take a sample composed of few DNA molecules and amplify a specific DNA sequence; lateral flow devices (LFDs), one of the tools that can be used to support the diagnosis of COVID-19, the LFD detects a COVID-19 antigen that appears in the sample of a person that is or was infected with SARS-CoV-2; biosensor, an analytical device, used for the detection of a biological/chemical substance that combines a biological component (receptor) with a physicochemical transducer

AUTHOR INFORMATION

Corresponding Authors

*Frank Vollmer, f.vollmer@exeter.ac.uk
*Justin Pepperell, Justin.Pepperell@SomersetFT.nhs.uk

Author Contributions

All authors have given approval to the final version of the manuscript. [⊥]These authors contributed equally.

REFERENCES

1.   Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; Chen, H.-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.-D.; Liu, M.-Q.; Chen, Y.; Shen, X.-R.; Wang, X.; Zheng, X.-S.; Zhao, K.; Chen, Q.-J.; Deng, F.; Liu, L.-L.; Yan, B.; Zhan, F.-X.; Wang, Y.-Y.; Xiao, G.-F.; Shi, Z.-L., A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **2020,** *579*(7798), 270-273.

2.   Wu, J. T.; Leung, K.; Leung, G. M., Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* **2020,** *395*(10225), 689-697.

3.   Wu, F.; Zhao, S.; Yu, B.; Chen, Y.-M.; Wang, W.; Song, Z.-G.; Hu, Y.; Tao, Z.-W.; Tian, J.-H.; Pei, Y.-Y.; Yuan, M.-L.; Zhang, Y.-L.; Dai, F.-H.; Liu, Y.; Wang, Q.-M.; Zheng, J.-J.; Xu, L.; Holmes, E. C.; Zhang, Y.-Z., A new coronavirus associated with human respiratory disease in China. *Nature* **2020,** *579*(7798), 265-269.

4.   Wiersinga, W. J.; Rhodes, A.; Cheng, A. C.; Peacock, S. J.; Prescott, H. C., Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* **2020,** *324*(8), 782-793.

5.   Alexandersen, S.; Chamings, A.; Bhatta, T. R., SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. *Nature Communications* **2020,** *11*(1), 6059.

6.   Morawska, L.; Milton, D. K., It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19). *Clinical Infectious Diseases* **2020,** *71*(9), 2311-2313.

7.   World Health Organization, Weekly epidemiological update. 23 February 2021 ed.; https://www.who.int/publications/m/item/weekly-epidemiological-update--23-february-2021.

8.   Gorbalenya, A. E.; Baker, S. C.; Baric, R. S.; de Groot, R. J.; Drosten, C.; Gulyaeva, A. A.; Haagmans, B. L.; Lauber, C.; Leontovich, A. M.; Neuman, B. W.; Penzar, D.; Perlman, S.; Poon, L. L. M.; Samborskiy, D. V.; Sidorov, I. A.; Sola, I.; Ziebuhr, J.; Coronaviridae Study Group of the International Committee on Taxonomy of, V., The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology* **2020,** *5*(4), 536-544.

9.   Khailany, R. A.; Safdar, M.; Ozaslan, M., Genomic characterization of a novel SARS-CoV-2. *Gene Reports* **2020,** *19*, 100682.

10.   Klein, S.; Cortese, M.; Winter, S. L.; Wachsmuth-Melm, M.; Neufeldt, C. J.; Cerikan, B.; Stanifer, M. L.; Boulant, S.; Bartenschlager, R.; Chlanda, P., SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. *Nature Communications* **2020,** *11*(1), 5885.

11.   Goldsmith, C. S.; Tatti, K. M.; Ksiazek, T. G.; Rollin, P. E.; Comer, J. A.; Lee, W. W.; Rota, P. A.; Bankamp, B.; Bellini, W. J.; Zaki, S. R., Ultrastructural characterization of SARS coronavirus. *Emerg Infect Dis* **2004,** *10*(2), 320-326.

12.   Andersen, K. G.; Rambaut, A.; Lipkin, W. I.; Holmes, E. C.; Garry, R. F., The proximal origin of SARS-CoV-2. *Nature Medicine* **2020,** *26*(4), 450-452.

13.   Hui, D. S. C.; Chan, M. C. H.; Wu, A. K.; Ng, P. C., Severe acute respiratory syndrome (SARS): epidemiology and clinical features. *Postgraduate Medical Journal* **2004,** *80*(945), 373.

14.   Petersen, E.; Koopmans, M.; Go, U.; Hamer, D. H.; Petrosillo, N.; Castelli, F.; Storgaard, M.; Al Khalili, S.; Simonsen, L., Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. *The Lancet Infectious Diseases* **2020,** *20*(9), e238-e244.

15.   Su, S.; Wong, G.; Shi, W.; Liu, J.; Lai, A. C. K.; Zhou, J.; Liu, W.; Bi, Y.; Gao, G. F., Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. *Trends in Microbiology* **2016,** *24*(6), 490-502.

16.   Zhang, Y.-Z.; Holmes, E. C., A Genomic Perspective on the Origin and Emergence of SARS-CoV-2. *Cell* **2020,** *181*(2), 223-227.

17.   Tang, X.; Wu, C.; Li, X.; Song, Y.; Yao, X.; Wu, X.; Duan, Y.; Zhang, H.; Wang, Y.; Qian, Z.; Cui, J.; Lu, J., On the origin and continuing evolution of SARS-CoV-2. *National Science Review* **2020,** *7*(6), 1012-1023.

18.   Minskaia, E.; Hertzig, T.; Gorbalenya, A. E.; Campanacci, V.; Cambillau, C.; Canard, B.; Ziebuhr, J., Discovery of an RNA virus 3′→5′ exoribonuclease that is critically involved in coronavirus RNA synthesis. *Proceedings of the National Academy of Sciences of the United States of America* **2006,** *103* (13), 5108.

19.   Lauring, A. S.; Hodcroft, E. B., Genetic Variants of SARS-CoV-2—What Do They Mean? *JAMA* **2021,** *325* (6), 529-531.

20.   du Plessis, L.; McCrone, J. T.; Zarebski, A. E.; Hill, V.; Ruis, C.; Gutierrez, B.; Raghwani, J.; Ashworth, J.; Colquhoun, R.; Connor, T. R.; Faria, N. R.; Jackson, B.; Loman, N. J.; O'Toole, Á.; Nicholls, S. M.; Parag, K. V.; Scher, E.; Vasylyeva, T. I.; Volz, E. M.; Watts, A.; Bogoch, I. I.; Khan, K.; Aanensen, D. M.; Kraemer, M. U. G.; Rambaut, A.; Pybus, O. G., Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK. *Science* **2021,** *371* (6530), 708.

21.   Davies, N. G.; Jarvis, C. I.; van Zandvoort, K.; Clifford, S.; Sun, F. Y.; Funk, S.; Medley, G.; Jafari, Y.; Meakin, S. R.; Lowe, R.; Quaife, M.; Waterlow, N. R.; Eggo, R. M.; Lei, J.; Koltai, M.; Krauer, F.; Tully, D. C.; Munday, J. D.; Showering, A.; Foss, A. M.; Prem, K.; Flasche, S.; Kucharski, A. J.; Abbott, S.; Quilty, B. J.; Jombart, T.; Rosello, A.; King, M.; Jit, M.; Liu, Y.; Williams, J.; Hellewell, J.; O'Reilly, K.; Chan, Y.-W. D.; Russell, T. W.; Procter, S. R.; Endo, A.; Nightingale, E. S.; Bosse, N. I.; Villabona-Arenas, C. J.; Sandmann, F. G.; Gimma, A.; Abbas, K.; Waites, W.; Atkins, K. E.; Barnard, R. C.; Klepac, P.; Gibbs, H. P.; Pearson, C. A. B.; Brady, O.; Edmunds, W. J.; Jewell, N. P.; Diaz-Ordaz, K.; Keogh, R. H.; Group, C.-W., Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. *Nature* **2021.**

22.   Challen, R.; Brooks-Pollock, E.; Read, J. M.; Dyson, L.; Tsaneva-Atanasova, K.; Danon, L., Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ* **2021,** *372,* n579.

23.   Dudas, G.; Carvalho, L. M.; Bedford, T.; Tatem, A. J.; Baele, G.; Faria, N. R.; Park, D. J.; Ladner, J. T.; Arias, A.; Asogun, D.; Bielejec, F.; Caddy, S. L.; Cotten, M.; D'Ambrozio, J.; Dellicour, S.; Di Caro, A.; Diclaro, J. W.; Duraffour, S.; Elmore, M. J.; Fakoli, S.; Faye, O.; Gilbert, M. L.; Gevao, S. M.; Gire, S.; Gladden-Young, A.; Gnirke, A.; Goba, A.; Grant, D. S.; Haagmans, B. L.; Hiscox, J. A.; Jah, U.; Kugelman, J. R.; Liu, D.; Lu, J.; Malboeuf, C. M.; Mate, S.; Matthews, D. A.; Matranga, C. B.; Meredith, L. W.; Qu, J.; Quick, J.; Pas, S. D.; Phan, M. V. T.; Pollakis, G.; Reusken, C. B.; Sanchez-Lockhart, M.; Schaffner, S. F.; Schieffelin, J. S.; Sealfon, R. S.; Simon-Loriere, E.; Smits, S. L.; Stoecker, K.; Thorne, L.; Tobin, E. A.; Vandi, M. A.; Watson, S. J.; West, K.; Whitmer, S.; Wiley, M. R.; Winnicki, S. M.; Wohl, S.; Wölfel, R.; Yozwiak, N. L.; Andersen, K. G.; Blyden, S. O.; Bolay, F.; Carroll, M. W.; Dahn, B.; Diallo, B.; Formenty, P.; Fraser, C.; Gao, G. F.; Garry, R. F.; Goodfellow, I.; Günther, S.; Happi, C. T.; Holmes, E. C.; Kargbo, B.; Keïta, S.; Kellam, P.; Koopmans, M. P. G.; Kuhn, J. H.; Loman, N. J.; Magassouba, N. F.; Naidoo, D.; Nichol, S. T.; Nyenswah, T.; Palacios, G.; Pybus, O. G.; Sabeti, P. C.; Sall, A.; Ströher, U.; Wurie, I.; Suchard, M. A.; Lemey, P.; Rambaut, A., Virus genomes reveal factors that spread and sustained the Ebola epidemic. *Nature* **2017,** *544* (7650), 309-315.

24.   Baillie, G. J.; Galiano, M.; Agapow, P.-M.; Myers, R.; Chiam, R.; Gall, A.; Palser, A. L.; Watson, S. J.; Hedge, J.; Underwood, A.; Platt, S.; McLean, E.; Pebody, R. G.; Rambaut, A.; Green, J.; Daniels, R.; Pybus, O. G.; Kellam, P.; Zambon, M., Evolutionary Dynamics of Local Pandemic H1N1/2009 Influenza Virus Lineages Revealed by Whole-Genome Analysis. *Journal of Virology* **2012,** *86* (1), 11.

25.   consortiumcontact@cogconsortium.uk,-C. U., An integrated national scale SARS-CoV-2 genomic surveillance network. *Lancet Microbe* **2020,** *1* (3), e99-e100.

26.   Volz, E.; Hill, V.; McCrone, J. T.; Price, A.; Jorgensen, D.; O'Toole, Á.; Southgate, J.; Johnson, R.; Jackson, B.; Nascimento, F. F.; Rey, S. M.; Nicholls, S. M.; Colquhoun, R. M.; da Silva Filipe, A.; Shepherd, J.; Pascall, D. J.; Shah, R.; Jesudason, N.; Li, K.; Jarrett, R.; Pacchiarini, N.; Bull, M.; Geidelberg, L.; Siveroni, I.; Koshy, C.; Wise, E.; Cortes, N.; Lynch, J.; Kidd, S.; Mori, M.; Fairley, D. J.; Curran, T.; McKenna, J. P.; Adams, H.; Fraser, C.; Golubchik, T.; Bonsall, D.; Moore, C.; Caddy, S. L.; Khokhar, F. A.; Wantoch, M.; Reynolds, N.; Warne, B.; Maksimovic,

J.; Spellman, K.; McCluggage, K.; John, M.; Beer, R.; Afifi, S.; Morgan, S.; Marchbank, A.; Price, A.; Kitchen, C.; Gulliver, H.; Merrick, I.; Southgate, J.; Guest, M.; Munn, R.; Workman, T.; Connor, T. R.; Fuller, W.; Bresner, C.; Snell, L. B.; Charalampous, T.; Nebbia, G.; Batra, R.; Edgeworth, J.; Robson, S. C.; Beckett, A.; Loveson, K. F.; Aanensen, D. M.; Underwood, A. P.; Yeats, C. A.; Abudahab, K.; Taylor, B. E. W.; Menegazzo, M.; Clark, G.; Smith, W.; Khakh, M.; Fleming, V. M.; Lister, M. M.; Howson-Wells, H. C.; Berry, L.; Boswell, T.; Joseph, A.; Willingham, I.; Bird, P.; Helmer, T.; Fallon, K.; Holmes, C.; Tang, J.; Raviprakash, V.; Campbell, S.; Sheriff, N.; Loose, M. W.; Holmes, N.; Moore, C.; Carlile, M.; Wright, V.; Sang, F.; Debebe, J.; Coll, F.; Signell, A. W.; Betancor, G.; Wilson, H. D.; Feltwell, T.; Houldcroft, C. J.; Eldirdiri, S.; Kenyon, A.; Davis, T.; Pybus, O.; du Plessis, L.; Zarebski, A.; Raghwani, J.; Kraemer, M.; Francois, S.; Attwood, S.; Vasylyeva, T.; Torok, M. E.; Hamilton, W. L.; Goodfellow, I. G.; Hall, G.; Jahun, A. S.; Chaudhry, Y.; Hosmillo, M.; Pinckert, M. L.; Georgana, I.; Yakovleva, A.; Meredith, L. W.; Moses, S.; Lowe, H.; Ryan, F.; Fisher, C. L.; Awan, A. R.; Boyes, J.; Breuer, J.; Harris, K. A.; Brown, J. R.; Shah, D.; Atkinson, L.; Lee, J. C. D.; Alcolea-Medina, A.; Moore, N.; Cortes, N.; Williams, R.; Chapman, M. R.; Levett, L. J.; Heaney, J.; Smith, D. L.; Bashton, M.; Young, G. R.; Allan, J.; Loh, J.; Randell, P. A.; Cox, A.; Madona, P.; Holmes, A.; Bolt, F.; Price, J.; Mookerjee, S.; Rowan, A.; Taylor, G. P.; Ragonnet-Cronin, M.; Nascimento, F. F.; Jorgensen, D.; Siveroni, I.; Johnson, R.; Boyd, O.; Geidelberg, L.; Volz, E. M.; Brunker, K.; Smollett, K. L.; Loman, N. J.; Quick, J.; McMurray, C.; Stockton, J.; Nicholls, S.; Rowe, W.; Poplawski, R.; Martinez-Nunez, R. T.; Mason, J.; Robinson, T. I.; O'Toole, E.; Watts, J.; Breen, C.; Cowell, A.; Ludden, C.; Sluga, G.; Machin, N. W.; Ahmad, S. S. Y.; George, R. P.; Halstead, F.; Sivaprakasam, V.; Thomson, E. C.; Shepherd, J. G.; Asamaphan, P.; Niebel, M. O.; Li, K. K.; Shah, R. N.; Jesudason, N. G.; Parr, Y. A.; Tong, L.; Broos, A.; Mair, D.; Nichols, J.; Carmichael, S. N.; Nomikou, K.; Aranday-Cortes, E.; Johnson, N.; Starinskij, I.; da Silva Filipe, A.; Robertson, D. L.; Orton, R. J.; Hughes, J.; Vattipally, S.; Singer, J. B.; Hale, A. D.; Macfarlane-Smith, L. R.; Harper, K. L.; Taha, Y.; Payne, B. A. I.; Burton-Fanning, S.; Waugh, S.; Collins, J.; Eltringham, G.; Templeton, K. E.; McHugh, M. P.; Dewar, R.; Wastenge, E.; Dervisevic, S.; Stanley, R.; Prakash, R.; Stuart, C.; Elumogo, N.; Sethi, D. K.; Meader, E. J.; Coupland, L. J.; Potter, W.; Graham, C.; Barton, E.; Padgett, D.; Scott, G.; Swindells, E.; Greenaway, J.; Nelson, A.; Yew, W. C.; Resende Silva, P. C.; Andersson, M.; Shaw, R.; Peto, T.; Justice, A.; Eyre, D.; Crooke, D.; Hoosdally, S.; Sloan, T. J.; Duckworth, N.; Walsh, S.; Chauhan, A. J.; Glaysher, S.; Bicknell, K.; Wyllie, S.; Butcher, E.; Elliott, S.; Lloyd, A.; Impey, R.; Levene, N.; Monaghan, L.; Bradley, D. T.; Allara, E.; Pearson, C.; Muir, P.; Vipond, I. B.; Hopes, R.; Pymont, H. M.; Hutchings, S.; Curran, M. D.; Parmar, S.; Lackenby, A.; Mbisa, T.; Platt, S.; Miah, S.; Bibby, D.; Manso, C.; Hubb, J.; Chand, M.; Dabrera, G.; Ramsay, M.; Bradshaw, D.; Thornton, A.; Myers, R.; Schaefer, U.; Groves, N.; Gallagher, E.; Lee, D.; Williams, D.; Ellaby, N.; Harrison, I.; Hartman, H.; Manesis, N.; Patel, V.; Bishop, C.; Chalker, V.; Osman, H.; Bosworth, A.; Robinson, E.; Holden, M. T. G.; Shaaban, S.; Birchley, A.; Adams, A.; Davies, A.; Gaskin, A.; Plimmer, A.; Gatica-Wilcox, B.; McKerr, C.; Moore, C.; Williams, C.; Heyburn, D.; De Lacy, E.; Hilvers, E.; Downing, F.; Shankar, G.; Jones, H.; Asad, H.; Coombes, J.; Watkins, J.; Evans, J. M.; Fina, L.; Gifford, L.; Gilbert, L.; Graham, L.; Perry, M.; Morgan, M.; Bull, M.; Cronin, M.; Pacchiarini, N.; Craine, N.; Jones, R.; Howe, R.; Corden, S.; Rey, S.; Kumziene-Summerhayes, S.; Taylor, S.; Cottrell, S.; Jones, S.; Edwards, S.; O'Grady, J.; Page, A. J.; Wain, J.; Webber, M. A.; Mather, A. E.; Baker, D. J.; Rudder, S.; Yasir, M.; Thomson, N. M.; Aydin, A.; Tedim, A. P.; Kay, G. L.; Trotter, A. J.; Gilroy, R. A. J.; Alikhan, N.-F.; de Oliveira Martins, L.; Le-Viet, T.; Meadows, L.; Kolyva, A.; Diaz, M.; Bell, A.; Gutierrez, A. V.; Charles, I. G.; Adriaenssens, E. M.; Kingsley, R. A.; Casey, A.; Simpson, D. A.; Molnar, Z.; Thompson, T.; Acheson, E.; Masoli, J. A. H.; Knight, B. A.; Hattersley, A.; Ellard, S.; Auckland, C.; Mahungu, T. W.; Irish-Tavares, D.; Haque, T.; Bourgeois, Y.; Scarlett, G. P.; Partridge, D. G.; Raza, M.; Evans, C.; Johnson, K.; Liggett, S.; Baker, P.; Essex, S.; Lyons, R. A.; Caller, L. G.; Castellano, S.; Williams, R. J.; Kristiansen, M.; Roy, S.; Williams, C. A.; Dyal, P. L.; Tutill, H. J.; Panchbhaya, Y. N.; Forrest, L. M.; Niola, P.; Findlay, J.; Brooks, T. T.; Gavriil, A.; Mestek-

Boukhibar, L.; Weeks, S.; Pandey, S.; Berry, L.; Jones, K.; Richter, A.; Beggs, A.; Smith, C. P.; Bucca, G.; Hesketh, A. R.; Harrison, E. M.; Peacock, S. J.; Palmer, S.; Churcher, C. M.; Bellis, K. L.; Girgis, S. T.; Naydenova, P.; Blane, B.; Sridhar, S.; Ruis, C.; Forrest, S.; Cormie, C.; Gill, H. K.; Dias, J.; Higginson, E. E.; Maes, M.; Young, J.; Kermack, L. M.; Hadjirin, N. F.; Aggarwal, D.; Griffith, L.; Swingler, T.; Davidson, R. K.; Rambaut, A.; Williams, T.; Balcazar, C. E.; Gallagher, M. D.; O'Toole, Á.; Rooke, S.; Jackson, B.; Colquhoun, R.; Ashworth, J.; Hill, V.; McCrone, J. T.; Scher, E.; Yu, X.; Williamson, K. A.; Stanton, T. D.; Michell, S. L.; Bewshea, C. M.; Temperton, B.; Michelsen, M. L.; Warwick-Dugdale, J.; Manley, R.; Farbos, A.; Harrison, J. W.; Sambles, C. M.; Studholme, D. J.; Jeffries, A. R.; Darby, A. C.; Hiscox, J. A.; Paterson, S.; Iturriza-Gomara, M.; Jackson, K. A.; Lucaci, A. O.; Vamos, E. E.; Hughes, M.; Rainbow, L.; Eccles, R.; Nelson, C.; Whitehead, M.; Turtle, L.; Haldenby, S. T.; Gregory, R.; Gemmell, M.; Kwiatkowski, D.; de Silva, T. I.; Smith, N.; Angyal, A.; Lindsey, B. B.; Groves, D. C.; Green, L. R.; Wang, D.; Freeman, T. M.; Parker, M. D.; Keeley, A. J.; Parsons, P. J.; Tucker, R. M.; Brown, R.; Wyles, M.; Constantinidou, C.; Unnikrishnan, M.; Ott, S.; Cheng, J. K. J.; Bridgewater, H. E.; Frost, L. R.; Taylor-Joyce, G.; Stark, R.; Baxter, L.; Alam, M. T.; Brown, P. E.; McClure, P. C.; Chappell, J. G.; Tsoleridis, T.; Ball, J.; Gramatopoulos, D.; Buck, D.; Todd, J. A.; Green, A.; Trebes, A.; MacIntyre-Cockett, G.; de Cesare, M.; Langford, C.; Alderton, A.; Amato, R.; Goncalves, S.; Jackson, D. K.; Johnston, I.; Sillitoe, J.; Palmer, S.; Lawniczak, M.; Berriman, M.; Danesh, J.; Livett, R.; Shirley, L.; Farr, B.; Quail, M.; Thurston, S.; Park, N.; Betteridge, E.; Weldon, D.; Goodwin, S.; Nelson, R.; Beaver, C.; Letchford, L.; Jackson, D. A.; Foulser, L.; McMinn, L.; Prestwood, L.; Kay, S.; Kane, L.; Dorman, M. J.; Martincorena, I.; Puethe, C.; Keatley, J.-P.; Tonkin-Hill, G.; Smith, C.; Jamrozy, D.; Beale, M. A.; Patel, M.; Ariani, C.; Spencer-Chapman, M.; Drury, E.; Lo, S.; Rajatileka, S.; Scott, C.; James, K.; Buddenborg, S. K.; Berger, D. J.; Patel, G.; Garcia-Casado, M. V.; Dibling, T.; McGuigan, S.; Rogers, H. A.; Hunter, A. D.; Souster, E.; Neaverson, A. S.; Goodfellow, I.; Loman, N. J.; Pybus, O. G.; Robertson, D. L.; Thomson, E. C.; Rambaut, A.; Connor, T. R., Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. *Cell* 2021, *184* (1), 64-75.e11.

27. Volz, E.; Mishra, S.; Chand, M.; Barrett, J. C.; Johnson, R.; Geidelberg, L.; Hinsley, W. R.; Laydon, D. J.; Dabrera, G.; O'Toole, Á.; Amato, R.; Ragonnet-Cronin, M.; Harrison, I.; Jackson, B.; Ariani, C. V.; Boyd, O.; Loman, N. J.; McCrone, J. T.; Gonçalves, S.; Jorgensen, D.; Myers, R.; Hill, V.; Jackson, D. K.; Gaythorpe, K.; Groves, N.; Sillitoe, J.; Kwiatkowski, D. P.; Flaxman, S.; Ratmann, O.; Bhatt, S.; Hopkins, S.; Gandy, A.; Rambaut, A.; Ferguson, N. M., Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. *medRxiv* 2021, 2020.12.30.20249034.

28. Davies, N. G.; Barnard, R. C.; Jarvis, C. I.; Kucharski, A. J.; Munday, J. D.; Pearson, C. A. B.; Russell, T. W.; Tully, D. C.; Abbott, S.; Gimma, A.; Waites, W.; Wong, K. L. M.; van Zandvoort, K.; Eggo, R. M.; Funk, S.; Jit, M.; Atkins, K. E.; Edmunds, W. J., Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. *medRxiv* 2020, 2020.12.24.20248822.

29. Grubaugh, N. D.; Hodcroft, E. B.; Fauver, J. R.; Phelan, A. L.; Cevik, M., Public health actions to control new SARS-CoV-2 variants. *Cell* 2021, *184* (5), 1127-1132.

30. Corman, V. M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D. K.; Bleicker, T.; Brünink, S.; Schneider, J.; Schmidt, M. L.; Mulders, D. G.; Haagmans, B. L.; van der Veer, B.; van den Brink, S.; Wijsman, L.; Goderski, G.; Romette, J.-L.; Ellis, J.; Zambon, M.; Peiris, M.; Goossens, H.; Reusken, C.; Koopmans, M. P.; Drosten, C., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin* 2020, *25* (3), 2000045.

31. Mendoza, E. J.; Manguiat, K.; Wood, H.; Drebot, M., Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2. *Current Protocols in Microbiology* 2020, *57* (1), cpmc105.

32. Shors, T., *Understanding viruses*. Third ed.; Jones & Bartlett Learning: Burlington, MA, 2017.

33. Madigan, M. T.; Martinko, J. M.; Dunlap, P. V., *Brock Biology of Microorganisms*, 12th ed.; Pearson Benjamin Cummings: San Francisco, CA, 2009.

34. van Doremalen, N.; Bushmaker, T.; Morris, D. H.; Holbrook, M. G.; Gamble, A.; Williamson, B. N.; Tamin, A.; Harcourt, J. L.; Thornburg, N. J.; Gerber, S. I.; Lloyd-Smith, J. O.; de Wit, E.; Munster, V. J., Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *New England Journal of Medicine* 2020, *382* (16), 1564-1567.

35. Zhou, F.; Fan, G.; Liu, Z.; Cao, B., SARS-CoV-2 shedding and infectivity – Authors' reply. *The Lancet* 2020, *395* (10233), 1340.

36. Mesa Vieira, C.; Franco, O. H.; Gómez-Restrepo, C.; Abel, T., COVID-19: The forgotten priorities of the pandemic. *Maturitas* 2020, *136*, 38-41.

37. Kosack, C. S.; Page, A.-L.; Klatser, P. R., A guide to aid the selection of diagnostic tests. *Bull. World Health Organ.* 2017, *95* (9), 639-645.

38. Vandenberg, O.; Martiny, D.; Rochas, O.; van Belkum, A.; Kozlakidis, Z., Considerations for diagnostic COVID-19 tests. *Nature Reviews Microbiology* 2021, *19* (3), 171-183.

39. Ainsworth, M.; Andersson, M.; Auckland, K.; Baillie, J. K.; Barnes, E.; Beer, S.; Beveridge, A.; Bibi, S.; Blackwell, L.; Borak, M.; Bown, A.; Brooks, T.; Burgess-Brown, N. A.; Camara, S.; Catton, M.; Chau, K. K.; Christott, T.; Clutterbuck, E.; Coker, J.; Cornall, R. J.; Cox, S.; Crawford-Jones, D.; Crook, D. W.; D'Arcangelo, S.; Dejnirattsai, W.; Dequaire, J. M. M.; Dimitriadis, S.; Dingle, K. E.; Doherty, G.; Dold, C.; Dong, T.; Dunachie, S. J.; Ebner, D.; Emmenegger, M.; Espinosa, A.; Eyre, D. W.; Fairhead, R.; Fassih, S.; Feehily, C.; Felle, S.; Fernandez-Cid, A.; Fernandez Mendoza, M.; Foord, T. H.; Fordwoh, T.; Fox McKee, D.; Frater, J.; Gallardo Sanchez, V.; Gent, N.; Georgiou, D.; Groves, C. J.; Hallis, B.; Hammond, P. M.; Hatch, S. B.; Harvala, H. J.; Hill, J.; Hoosdally, S. J.; Horsington, B.; Howarth, A.; James, T.; Jeffery, K.; Jones, E.; Justice, A.; Karpe, F.; Kavanagh, J.; Kim, D. S.; Kirton, R.; Klenerman, P.; Knight, J. C.; Koukouflis, L.; Kwok, A.; Leuschner, U.; Levin, R.; Linder, A.; Lockett, T.; Lumley, S. F.; Marinou, S.; Marsden, B. D.; Martinez, J.; Martins Ferreira, L.; Mason, L.; Matthews, P. C.; Mentzer, A. J.; Mobbs, A.; Mongkolsapaya, J.; Morrow, J.; Mukhopadhyay, S. M. M.; Neville, M. J.; Oakley, S.; Oliveira, M.; Otter, A.; Paddon, K.; Pascoe, J.; Peng, Y.; Perez, E.; Perumal, P. K.; Peto, T. E. A.; Pickford, H.; Ploeg, R. J.; Pollard, A. J.; Richardson, A.; Ritter, T. G.; Roberts, D. J.; Rodger, G.; Rollier, C. S.; Rowe, C.; Rudkin, J. K.; Screaton, G.; Semple, M. G.; Sienkiewicz, A.; Silva-Reyes, L.; Skelly, D. T.; Sobrino Diaz, A.; Stafford, L.; Stockdale, L.; Stoesser, N.; Street, T.; Stuart, D. I.; Sweed, A.; Taylor, A.; Thraves, H.; Tsang, H. P.; Verheul, M. K.; Vipond, R.; Walker, T. M.; Wareing, S.; Warren, Y.; Wells, C.; Wilson, C.; Withycombe, K.; Young, R. K., Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *The Lancet Infectious Diseases* 2020, *20* (12), 1390-1400.

40. van Kasteren, P. B.; van der Veer, B.; van den Brink, S.; Wijsman, L.; de Jonge, J.; van den Brandt, A.; Molenkamp, R.; Reusken, C. B. E. M.; Meijer, A., Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. *Journal of Clinical Virology* 2020, *128*, 104412.

41. Tang, Y.-W.; Schmitz, J. E.; Persing, D. H.; Stratton, C. W., Laboratory Diagnosis of COVID-19: Current Issues and Challenges. *Journal of Clinical Microbiology* 2020, *58* (6), e00512-20.

42. Pan, Y.; Zhang, D.; Yang, P.; Poon, L. L. M.; Wang, Q., Viral load of SARS-CoV-2 in clinical samples. *Lancet Infect Dis* 2020, *20* (4), 411-412.

43. Thompson, D.; Lei, Y., Mini review: Recent progress in RT-LAMP enabled COVID-19 detection. *Sensors and Actuators Reports* 2020, *2* (1), 100017.

44. Lamb, L. E.; Bartolone, S. N.; Ward, E.; Chancellor, M. B., Rapid detection of novel coronavirus/Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated isothermal amplification. *PLoS One* 2020, *15* (6), e0234682-e0234682.

45. Dao Thi, V. L.; Herbst, K.; Boerner, K.; Meurer, M.; Kremer, L. P. M.; Kirrmaier, D.; Freistaedter, A.; Papagiannidis, D.; Galmozzi, C.; Stanifer, M. L.; Boulant, S.; Klein, S.; Chlanda, P.; Khalid, D.; Barreto Miranda, I.; Schnitzler, P.; Kräusslich, H.-G.; Knop, M.; Anders, S., A

colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. *Science Translational Medicine* **2020,** *12* (556), eabc7075.

46.   Ventura, B. D.; Cennamo, M.; Minopoli, A.; Campanile, R.; Censi, S. B.; Terracciano, D.; Portella, G.; Velotta, R., Colorimetric Test for Fast Detection of SARS-CoV-2 in Nasal and Throat Swabs. *ACS Sensors* **2020,** *5* (10), 3043-3048.

47.   Lu, R.; Wu, X.; Wan, Z.; Li, Y.; Zuo, L.; Qin, J.; Jin, X.; Zhang, C., Development of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2. *Virologica Sinica* **2020,** *35* (3), 344-347.

48.   Zhang, Y.; Odiwuor, N.; Xiong, J.; Sun, L.; Nyaruaba, R. O.; Wei, H.; Tanner, N. A., Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP. *medRxiv* **2020,** 2020.02.26.20028373.

49.   Broughton, J. P.; Deng, X.; Yu, G.; Fasching, C. L.; Servellita, V.; Singh, J.; Miao, X.; Streithorst, J. A.; Granados, A.; Sotomayor-Gonzalez, A.; Zorn, K.; Gopez, A.; Hsu, E.; Gu, W.; Miller, S.; Pan, C.-Y.; Guevara, H.; Wadford, D. A.; Chen, J. S.; Chiu, C. Y., CRISPR-Cas12-based detection of SARS-CoV-2. *Nature Biotechnology* **2020,** *38* (7), 870-874.

50.   Xiong, D.; Dai, W.; Gong, J.; Li, G.; Liu, N.; Wu, W.; Pan, J.; Chen, C.; Jiao, Y.; Deng, H.; Ye, J.; Zhang, X.; Huang, H.; Li, Q.; Xue, L.; Zhang, X.; Tang, G., Rapid detection of SARS-CoV-2 with CRISPR-Cas12a. *PLOS Biology* **2020,** *18* (12), e3000978.

51.   Huang, Z.; Tian, D.; Liu, Y.; Lin, Z.; Lyon, C. J.; Lai, W.; Fusco, D.; Drouin, A.; Yin, X.; Hu, T.; Ning, B., Ultrasensitive and high-throughput CRISPR-powered COVID-19 diagnosis. *Biosensors and Bioelectronics* **2020,** *164,* 112316.

52.   Guo, L.; Sun, X.; Wang, X.; Liang, C.; Jiang, H.; Gao, Q.; Dai, M.; Qu, B.; Fang, S.; Mao, Y.; Chen, Y.; Feng, G.; Gu, Q.; Wang, R. R.; Zhou, Q.; Li, W., SARS-CoV-2 detection with CRISPR diagnostics. *Cell Discovery* **2020,** *6* (1), 34.

53.   Ning, B.; Yu, T.; Zhang, S.; Huang, Z.; Tian, D.; Lin, Z.; Niu, A.; Golden, N.; Hensley, K.; Threeton, B.; Lyon, C. J.; Yin, X.-M.; Roy, C. J.; Saba, N. S.; Rappaport, J.; Wei, Q.; Hu, T. Y., A smartphone-read ultrasensitive and quantitative saliva test for COVID-19. *Science Advances* **2021,** *7* (2), eabe3703.

54.   Richter, A.; Plant, T.; Kidd, M.; Bosworth, A.; Mayhew, M.; Megram, O.; Ashworth, F.; Crawford, L.; White, T.; Moles-Garcia, E.; Mirza, J.; Percival, B.; McNally, A., How to establish an academic SARS-CoV-2 testing laboratory. *Nature Microbiology* **2020,** *5* (12), 1452-1454.

55.   Gibani, M. M.; Toumazou, C.; Sohbati, M.; Sahoo, R.; Karvela, M.; Hon, T.-K.; De Mateo, S.; Burdett, A.; Leung, K. Y. F.; Barnett, J.; Orbeladze, A.; Luan, S.; Pournias, S.; Sun, J.; Flower, B.; Bedzo-Nutakor, J.; Amran, M.; Quinlan, R.; Skolimowska, K.; Herrera, C.; Rowan, A.; Badhan, A.; Klaber, R.; Davies, G.; Muir, D.; Randell, P.; Crook, D.; Taylor, G. P.; Barclay, W.; Mughal, N.; Moore, L. S. P.; Jeffery, K.; Cooke, G. S., Assessing a novel, fully automated point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. *The Lancet Microbe* **2020,** *1* (7), e300-e307.

56.   Rodriguez-Manzano, J.; Malpartida-Cardenas, K.; Moser, N.; Pennisi, I.; Cavuto, M.; Miglietta, L.; Moniri, A.; Penn, R.; Satta, G.; Randell, P.; Davies, F.; Bolt, F.; Barclay, W.; Holmes, A.; Georgiou, P., Handheld Point-of-Care System for Rapid Detection of SARS-CoV-2 Extracted RNA in under 20 min. *ACS Central Science* **2021,** *7* (2), 307-317.

57.   Qiu, G.; Gai, Z.; Tao, Y.; Schmitt, J.; Kullak-Ublick, G. A.; Wang, J., Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection. *ACS Nano* **2020,** *14* (5), 5268-5277.

58.   La Marca, A.; Capuzzo, M.; Paglia, T.; Roli, L.; Trenti, T.; Nelson, S. M., Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. *Reprod Biomed Online* **2020,** *41* (3), 483-499.

59.   Cheng, M. P.; Papenburg, J.; Desjardins, M.; Kanjilal, S.; Quach, C.; Libman, M.; Dittrich, S.; Yansouni, C. P., Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review. *Ann Intern Med* **2020,** *172* (11), 726-734.

60.   Alsharif, W.; Qurashi, A., Effectiveness of COVID-19 diagnosis and management tools: A review. *Radiography* **2020**.

61.   Wu, S. Y.; Yau, H. S.; Yu, M. Y.; Tsang, H. F.; Chan, L. W. C.; Cho, W. C. S.; Shing Yu, A. C.; Yuen Yim, A. K.; Li, M. J. W., Wong, Y. K. E.; Pei, X. M.; Cesar Wong, S. C., The diagnostic methods in the COVID-19 pandemic, today and in the future. *Expert Review of Molecular Diagnostics* **2020**, *20* (9), 985-993.

62.   Mohammadi, A.; Esmaeilzadeh, E.; Li, Y.; Bosch, R. J.; Li, J. Z., SARS-CoV-2 Detection in Different Respiratory Sites: A Systematic Review and Meta-analysis. *medRxiv : the preprint server for health sciences* **2020**, 2020.05.14.20102038.

63.   Bradshaw, W. J.; Huggins, J. H.; Lloyd, A. L.; Esvelt, K. M., The feasibility of targeted test-trace-isolate for the control of SARS-CoV-2 variants. *medRxiv* **2021**, 2021.01.11.21249612.

64.   Lopez-Rincon, A.; Perez-Romero, C. A.; Tonda, A.; Mendoza-Maldonado, L.; Claassen, E.; Garssen, J.; Kraneveld, A. D., Design of Specific Primer Set for Detection of B.1.1.7 SARS-CoV-2 Variant using Deep Learning. *bioRxiv* **2020**, 2020.12.29.424715.

65.   Korukluoglu, G.; Kolukirik, M.; Bayrakdar, F.; Ozgumus, G. G.; Altas, A. B.; Cosgun, Y.; Ketre Kolukirik, C. Z., 40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations. *bioRxiv* **2021**, 2021.01.26.428302.

66.   Ji, T.; Liu, Z.; Wang, G.; Guo, X.; Akbar khan, S.; Lai, C.; Chen, H.; Huang, S.; Xia, S.; Chen, B.; Jia, H.; Chen, Y.; Zhou, Q., Detection of COVID-19: A review of the current literature and future perspectives. *Biosensors and Bioelectronics* **2020**, *166*, 112455.

67.   Dinnes, J.; Deeks, J. J.; Adriano, A.; Berhane, S.; Davenport, C.; Dittrich, S.; Emperador, D.; Takwoingi, Y.; Cunningham, J.; Beese, S.; et al., Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database of Systematic Reviews* **2020**, (8).

68.   Peto, T., COVID-19: Rapid Antigen detection for SARS-CoV-2 by lateral flow assay: a national systematic evaluation for mass-testing. *medRxiv* **2021**, 2021.01.13.21249563.

69.   Mak, G. C. K.; Lau, S. S. Y.; Wong, K. K. Y.; Chow, N. L. S.; Lau, C. S.; Lam, E. T. K.; Chan, R. C. W.; Tsang, D. N. C., Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection of SARS-CoV-2 virus. *Journal of Clinical Virology* **2020**, *133*, 104684.

70.   Satyendra C Tripathi; Vishwajit Deshmukh; Ashlesh Patil; Tripathy, J. P., COVID 19 diagnostic multiplicity and its role in community surveillance and control. *Infez Med* **2020**, *28*, 18-28.

71.   Guo, L.; Ren, L.; Yang, S.; Xiao, M.; Chang, D.; Yang, F.; Dela Cruz, C. S.; Wang, Y.; Wu, C.; Xiao, Y.; Zhang, L.; Han, L.; Dang, S.; Xu, Y.; Yang, Q.-W.; Xu, S.-Y.; Zhu, H.-D.; Xu, Y.-C.; Jin, Q.; Sharma, L.; Wang, L.; Wang, J., Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clinical Infectious Diseases* **2020**, *71* (15), 778-785.

72.   Young, B. E.; Ong, S. W. X.; Ng, L. F. P.; Anderson, D. E.; Chia, W. N.; Chia, P. Y.; Ang, L. W.; Mak, T.-M.; Kalimuddin, S.; Chai, L. Y. A.; Pada, S.; Tan, S. Y.; Sun, L.; Parthasarathy, P.; Fong, S.-W.; Chan, Y.-H.; Tan, C. W.; Lee, B.; Rötzschke, O.; Ding, Y.; Tambyah, P.; Low, J. G. H.; Cui, L.; Barkham, T.; Lin, R. T. P.; Leo, Y.-S.; Renia, L.; Wang, L.-F.; Lye, D. C.; Singapore Novel Coronavirus Outbreak Research, T., Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. *Clinical Infectious Diseases* **2020**.

73.   Lumley, S. F.; Wei, J.; O'Donnell, D.; Stoesser, N. E.; Matthews, P. C.; Howarth, A.; Hatch, S. B.; Marsden, B. D.; Cox, S.; James, T.; Peck, L. J.; Ritter, T. G.; de Toledo, Z.; Cornall, R. J.; Jones, E. Y.; Stuart, D. I.; Screaton, G.; Ebner, D.; Hoosdally, S.; Crook, D. W.; Conlon, C. P.; Pouwels, K. B.; Walker, A. S.; Peto, T. E. A.; Walker, T. M.; Jeffery, K.; Eyre, D. W.; Oxford University Hospitals Staff Testing, G., The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. *Clinical Infectious Diseases* **2021**.

74.   Hansen, C. B.; Jarlhelt, I.; Pérez-Alós, L.; Hummelshøj Landsy, L.; Loftager, M.; Rosbjerg, A.; Helgstrand, C.; Bjelke, J. R.; Egebjerg, T.; Jardine, J. G.; Sværke Jørgensen, C.; Iversen, K.; Bayarri-Olmos, R.; Garred, P.; Skjoedt, M.-O., SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals. *The Journal of Immunology* **2021**, *206* (1), 109.

75.   Duysburgh, E.; Mortgat, L.; Barbezange, C.; Dierick, K.; Fischer, N.; Heyndrickx, L.; Hutse, V.; Thomas, I.; Van Gucht, S.; Vuylsteke, B.; Ariën, K. K.; Desombere, I., Persistence of IgG response to SARS-CoV-2. *Lancet Infect Dis* **2021,** *21* (2), 163-164.

76.   Liu, R.; Liu, X.; Yuan, L.; Han, H.; Shereen, M. A.; Zhen, J.; Niu, Z.; Li, D.; Liu, F.; Wu, K.; Luo, Z.; Zhu, C., Analysis of adjunctive serological detection to nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis. *Int Immunopharmacol* **2020,** *86,* 106746-106746.

77.   Pandey, R.; Gourishankar, A., Diagnostic Accuracy of FDA Authorized Serology Tests to Detect SARS-CoV-2 Antibodies: A Systematic Review and Meta-analysis. *medRxiv* **2020,** 2020.10.07.20208553.

78.   Deeks, J. J.; Dinnes, J.; Takwoingi, Y.; Davenport, C.; Spijker, R.; Taylor-Phillips, S.; Adriano, A.; Beese, S.; Dretzke, J.; Ferrante di Ruffano, L.; et al., Antibody tests for identification of current and past infection with SARS-CoV-2. *Cochrane Database of Systematic Reviews* **2020,** (6).

79.   Risch, M.; Weber, M.; Thiel, S.; Grossmann, K.; Wohlwend, N.; Lung, T.; Hillmann, D.; Ritzler, M.; Ferrara, F.; Bigler, S.; Egli, K.; Bodmer, T.; Imperiali, M.; Salimi, Y.; Fleisch, F.; Cusini, A.; Renz, H.; Kohler, P.; Vernazza, P.; Kahlert, C. R.; Paprotny, M.; Risch, L., Temporal Course of SARS-CoV-2 Antibody Positivity in Patients with COVID-19 following the First Clinical Presentation. *Biomed Res Int* **2020,** *2020,* 9878453-9878453.

80.   Zhang, Z.-L.; Hou, Y.-L.; Li, D.-T.; Li, F.-Z., Diagnostic efficacy of anti-SARS-CoV-2 IgG/IgM test for COVID-19: A meta-analysis. *J Med Virol* **2021,** *93* (1), 366-374.

81.   Jarrom, D.; Elston, L.; Washington, J.; Prettyjohns, M.; Cann, K.; Myles, S.; Groves, P., Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. *BMJ Evidence-Based Medicine* **2020,** bmjebm-2020-111511.

82.   Lisboa Bastos, M.; Tavaziva, G.; Abidi, S. K.; Campbell, J. R.; Haraoui, L.-P.; Johnston, J. C.; Lan, Z.; Law, S.; MacLean, E.; Trajman, A.; Menzies, D.; Benedetti, A.; Ahmad Khan, F., Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ* **2020,** *370,* m2516.

83.   Adams, E. R.; Ainsworth, M.; Anand, R.; Andersson, M. I.; Auckland, K.; Baillie, J. K.; Barnes, E.; Beer, S.; Bell, J. I.; Berry, T.; Bibi, S.; Carroll, M.; Chinnakannan, S. K.; Clutterbuck, E.; Cornall, R. J.; Crook, D. W.; de Silva, T.; Dejnirattisai, W.; Dingle, K. E.; Dold, C.; Espinosa, A.; Eyre, D. W.; Farmer, H.; Fernandez Mendoza, M.; Georgiou, D.; Hoosdally, S. J.; Hunter, A.; Jefferey, K.; Kelly, D. F.; Klenerman, P.; Knight, J.; Knowles, C.; Kwok, A. J.; Leuschner, U.; Levin, R.; Liu, C.; López-Camacho, C.; Martinez, J.; Matthews, P. C.; McGivern, H.; Mentzer, A. J.; Milton, J.; Mongkolsapaya, J.; Moore, S. C.; Oliveira, M. S.; Pereira, F.; Perez, E.; Peto, T.; Ploeg, R. J.; Pollard, A.; Prince, T.; Roberts, D. J.; Rudkin, J. K.; Sanchez, V.; Screaton, G. R.; Semple, M. G.; Slon-Campos, J.; Skelly, D. T.; Smith, E. N.; Sobrinodiaz, A.; Staves, J.; Stuart, D. I.; Supasa, P.; Surik, T.; Thraves, H.; Tsang, P.; Turtle, L.; Walker, A. S.; Wang, B.; Washington, C.; Watkins, N.; Whitehouse, J.; National, C. T. S. A. P., Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. *Wellcome Open Res* **2020,** *5,* 139-139.

84.   Lou, B.; Li, T.-D.; Zheng, S.-F.; Su, Y.-Y.; Li, Z.-Y.; Liu, W.; Yu, F.; Ge, S.-X.; Zou, Q.-D.; Yuan, Q.; Lin, S.; Hong, C.-M.; Yao, X.-Y.; Zhang, X.-J.; Wu, D.-H.; Zhou, G.-L.; Hou, W.-H.; Li, T.-T.; Zhang, Y.-L.; Zhang, S.-Y.; Fan, J.; Zhang, J.; Xia, N.-S.; Chen, Y., Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. *European Respiratory Journal* **2020,** *56* (2), 2000763.

85.   Staines, H. M.; Kirwan, D. E.; Clark, D. J.; Adams, E. R.; Augustin, Y.; Byrne, R. L.; Cocozza, M.; Cubas-Atienzar, A. I.; Cuevas, L. E.; Cusinato, M.; Davies, B. M. O.; Davis, M.; Davis, P.; Duvoix, A.; Eckersley, N. M.; Forton, D.; Fraser, A. J.; Garrod, G.; Hadcocks, L.; Hu, Q.; Johnson, M.; Kay, G. A.; Klekotko, K.; Lewis, Z.; Macallan, D. C.; Mensah-Kane, J.; Menzies, S.; Monahan, I.; Moore, C. M.; Nebe-von-Caron, G.; Owen, S. I.; Sainter, C.; Sall, A. A.; Schouten, J.; Williams, C.; Wilkins, J.; Woolston, K.; Fitchett, J. R. A.; Krishna, S.; Planche, T., Dynamics of

IgG seroconversion and pathophysiology of COVID-19 infections. *medRxiv* **2020**, 2020.06.07.20124636.

86. Dortet, L.; Emeraud, C.; Vaulou-Fellous, C.; Khecharem, M.; Ronat, J.-B.; Fortineau, N.; Roque-Afonso, A.-M.; Naas, T., Rapid Determination of SARS-CoV-2 antibodies using a bedside, point-of-Care, serological test. *Emerg Microbes Infect* **2020**, *9* (1), 2212-2221.

87. Ong, D. S. Y.; de Man, S. J.; Lindeboom, F. A.; Koeleman, J. G. M., Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected coronavirus disease 2019 presenting to the hospital. *Clin Microbiol Infect* **2020**, *26* (8), 1094.e7-1094.e10.

88. Vu, S. L.; Jones, G.; Anna, F.; Rose, T.; Richard, J.-B.; Bernard-Stoecklin, S.; Goyard, S.; Demeret, C.; Helynck, O.; Robin, C.; Monnet, V.; Facci, L. P. d.; Ungeheuer, M.-N.; Léon, L.; Guillois, Y.; Filleul, L.; Charneau, P.; Lévy-Bruhl, D.; van der Werf, S.; Noel, H., Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance. *medRxiv* **2020**, 2020.10.20.20213116.

89. Ward, H.; Atchison, C.; Whitaker, M.; Ainslie, K. E. C.; Elliott, J.; Okell, L.; Redd, R.; Ashby, D.; Donnelly, C. A.; Barclay, W.; Darzi, A.; Cooke, G.; Riley, S.; Elliott, P., Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults. *medRxiv* **2020**, 2020.08.12.20173690.

90. Ward, H.; Cooke, G.; Atchison, C.; Whitaker, M.; Elliott, J.; Moshe, M.; Brown, J. C.; Flower, B.; Daunt, A.; Ainslie, K.; Ashby, D.; Donnelly, C.; Riley, S.; Darzi, A.; Barclay, W.; Elliott, P., Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. *medRxiv* **2020**, 2020.10.26.20219725.

91. Shields, A. M.; Faustini, S. E.; Perez-Toledo, M.; Jossi, S.; Allen, J. D.; Al-Taei, S.; Backhouse, C.; Dunbar, L.; Ebanks, D.; Emmanuel, B.; Faniyi, A. A.; Garvey, M. I.; Grinbergs, A.; McGinnell, G.; O'Neill, J.; Watanabe, Y.; Crispin, M.; Wraith, D. C.; Cunningham, A. F.; Drayson, M. T.; Richter, A. G., Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response. *medRxiv* **2020**, 2020.11.12.20230763.

92. Mulchandani, R.; Jones, H. E.; Taylor-Phillips, S.; Shute, J.; Perry, K.; Jamarani, S.; Brooks, T.; Charlett, A.; Hickman, M.; Oliver, I.; Kaptoge, S.; Danesh, J.; Di Angelantonio, E.; Ades, A. E.; Wyllie, D. H., Accuracy of UK Rapid Test Consortium (UK-RTC) "AbC-19 Rapid Test" for detection of previous SARS-CoV-2 infection in key workers: test accuracy study. *BMJ* **2020**, *371*, m4262.

93. Dortet, L.; Ronat, J.-B.; Vaulou-Fellous, C.; Langendorf, C.; Mendels, D.-A.; Emeraud, C.; Oueslati, S.; Girlich, D.; Chauvin, A.; Afdjei, A.; Bernabeu, S.; Le Pape, S.; Kallala, R.; Rochard, A.; Verstuyft, C.; Fortineau, N.; Roque-Afonso, A.-M.; Naas, T., Evaluating 10 Commercially Available SARS-CoV-2 Rapid Serological Tests by Use of the STARD (Standards for Reporting of Diagnostic Accuracy Studies) Method. *Journal of Clinical Microbiology* **2021**, *59* (2), e02342-20.

94. Manisty, C.; Otter, A. D.; Treibel, T. A.; McKnight, Á.; Altmann, D. M.; Brooks, T.; Noursadeghi, M.; Boyton, R. J.; Semper, A.; Moon, J. C., Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. *The Lancet*

95. Sahin, U.; Muik, A.; Derhovanessian, E.; Vogler, I.; Kranz, L. M.; Vormehr, M.; Baum, A.; Pascal, K.; Quandt, J.; Maurus, D.; Brachtendorf, S.; Lörks, V.; Sikorski, J.; Hilker, R.; Becker, D.; Eller, A.-K.; Grützner, J.; Boesler, C.; Rosenbaum, C.; Kühnle, M.-C.; Luxemburger, U.; Kemmer-Brück, A.; Langer, D.; Bexon, M.; Bolte, S.; Karikó, K.; Palanche, T.; Fischer, B.; Schultz, A.; Shi, P.-Y.; Fontes-Garfias, C.; Perez, J. L.; Swanson, K. A.; Loschko, J.; Scully, I. L.; Cutler, M.; Kalina, W.; Kyratsous, C. A.; Cooper, D.; Dormitzer, P. R.; Jansen, K. U.; Türeci, Ö., COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature* **2020**, *586* (7830), 594-599.

96. Widge, A. T.; Rouphael, N. G.; Jackson, L. A.; Anderson, E. J.; Roberts, P. C.; Makhene, M.; Chappell, J. D.; Denison, M. R.; Stevens, L. J.; Pruijssers, A. J.; McDermott, A. B.; Flach, B.; Lin, B. C.; Doria-Rose, N. A.; O'Dell, S.; Schmidt, S. D.; Neuzil, K. M.; Bennett, H.; Leav, B.;

Makowski, M.; Albert, J.; Cross, K.; Edara, V.-V.; Floyd, K.; Suthar, M. S.; Buchanan, W.; Luke, C. J.; Ledgerwood, J. E.; Mascola, J. R.; Graham, B. S.; Beigel, J. H., Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *2020,* *384*(1), 80-82.

97.   Ewer, K. J.; Barrett, J. R.; Belij-Rammerstorfer, S.; Sharpe, H.; Makinson, R.; Morter, R.; Flaxman, A.; Wright, D.; Bellamy, D.; Bittaye, M.; Dold, C.; Provine, N. M.; Aboagye, J.; Fowler, J.; Silk, S. E.; Alderson, J.; Aley, P. K.; Angus, B.; Berrie, E.; Bibi, S.; Cicconi, P.; Clutterbuck, E. A.; Chelysheva, I.; Folegatti, P. M.; Fuskova, M.; Green, C. M.; Jenkin, D.; Kerridge, S.; Lawrie, A.; Minassian, A. M.; Moore, M.; Mujadidi, Y.; Plested, E.; Poulton, I.; Ramasamy, M. N.; Robinson, H.; Song, R.; Snape, M. D.; Tarrant, R.; Voysey, M.; Watson, M. E. E.; Douglas, A. D.; Hill, A. V. S.; Gilbert, S. C.; Pollard, A. J.; Lambe, T.; Ali, A.; Allen, E.; Baker, M.; Barnes, E.; Borthwick, N.; Boyd, A.; Brown-O'Sullivan, C.; Burgoyne, J.; Byard, N.; Puig, I. C.; Cappuccini, F.; Cho, J.-S.; Cicconi, P.; Clark, E.; Crocker, W. E. M.; Datoo, M. S.; Davies, H.; Dunachie, S. J.; Edwards, N. J.; Elias, S. C.; Furze, J.; Gilbride, C.; Harris, S. A.; Hodgson, S. H. C.; Hou, M. M.; Jackson, S.; Jones, K.; Kailath, R.; King, L.; Larkworthy, C. W.; Li, Y.; Lias, A. M.; Linder, A.; Lipworth, S.; Ramon, R. L.; Madhavan, M.; Marlow, E.; Marshall, J. L.; Mentzer, A. J.; Morrison, H.; Noé, A.; Pipini, D.; Pulido-Gomez, D.; Lopez, F. R.; Ritchie, A. J.; Rudiansyah, I.; Sanders, H.; Shea, A.; Silk, S.; Spencer, A. J.; Tanner, R.; Themistocleous, Y.; Thomas, M.; Tran, N.; Truby, A.; Turner, C.; Turner, N.; Ulaszewska, M.; Worth, A. T.; Kingham-Page, L.; Alvarez, M. P. P.; Anslow, R.; Bates, L.; Beadon, K.; Beckley, R.; Beveridge, A.; Bijker, E. M.; Blackwell, L.; Burbage, J.; Camara, S.; Carr, M.; Colin-Jones, R.; Cooper, R.; Cunningham, C. J.; Demissie, T.; Maso, C. D.; Douglas, N.; Drake-Brockman, R.; Drury, R. E.; Emary, K. R. W.; Felle, S.; Feng, S.; Ford, K. J.; Francis, E.; Gracie, L.; Hamlyn, J.; Hanumunthadu, B.; Harrison, D.; Hart, T. C.; Hawkins, S.; Hill, J.; Howe, E.; Howell, N.; Jones, E.; Keen, J.; Kelly, S.; Kerr, D.; Khan, L.; Kinch, J.; Koleva, S.; Lees, E. A.; Lelliott, A.; Liu, X.; Marinou, S.; McEwan, J.; Morey, E.; Morshead, G.; Muller, J.; Munro, C.; Murphy, S.; Mweu, P.; Nuthall, E.; O'Brien, K.; O'Connor, D.; O'Reilly, P. J.; Oguti, B.; Osborne, P.; Owino, N.; Parker, K.; Pfafferott, K.; Provstgaard-Morys, S.; Ratcliffe, H.; Rawlinson, T.; Rhead, S.; Roberts, H.; Sanders, K.; Silva-Reyes, L.; Smith, C. C.; Smith, D. J.; Szigeti, A.; Thomas, T. M.; Thompson, A.; Tonks, S.; Varughese, R.; Vichos, I.; Walker, L.; White, C.; White, R.; Yao, X. L.; Conlon, C. P.; Frater, J.; Cifuentes, L.; Baleanu, I.; Bolam, E.; Boland, E.; Brenner, T.; Damratoski, B. E.; Datta, C.; Muhanna, O. E.; Fisher, R.; Galian-Rubio, P.; Hodges, G.; Jackson, F.; Liu, S.; Loew, L.; Morgans, R.; Morris, S. J.; Olchawski, V.; Oliveria, C.; Parracho, H.; Pabon, E. R.; Tahiri-Alaoui, A.; Taylor, K.; Williams, P.; Zizi, D.; Arbe-Barnes, E. H.; Baker, P.; Batten, A.; Downing, C.; Drake, J.; English, M. R.; Henry, J. A.; Iveson, P.; Killen, A.; King, T. B.; Larwood, J. P. J.; Mallett, G.; Mansatta, K.; Mirtorabi, N.; Patrick-Smith, M.; Perring, J.; Radia, K.; Roche, S.; Schofield, E.; Naude, R. t. W.; Towner, J.; Baker, N.; Bewley, K. R.; Brunt, E.; Buttigieg, K. R.; Charlton, S.; Coombes, N. S.; Elmore, M. J.; Godwin, K.; Hallis, B.; Knott, D.; McInroy, L.; Shaik, I.; Thomas, K.; Tree, J. A.; Blundell, C. L.; Cao, M.; Kelly, D.; Skelly, D. T.; Themistocleous, A.; Dong, T.; Field, S.; Hamilton, E.; Kelly, E.; Klenerman, P.; Knight, J. C.; Lie, Y.; Petropoulos, C.; Sedik, C.; Wrin, T.; Meddaugh, G.; Peng, Y.; Screaton, G.; Stafford, E.; the Oxford, C. V. T. G., T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. *Nature Medicine* *2021,* *27*(2), 270-278.

98.   Folegatti, P. M.; Ewer, K. J.; Aley, P. K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E. A.; Dold, C.; Faust, S. N.; Finn, A.; Flaxman, A. L.; Hallis, B.; Heath, P.; Jenkin, D.; Lazarus, R.; Makinson, R.; Minassian, A. M.; Pollock, K. M.; Ramasamy, M.; Robinson, H.; Snape, M.; Tarrant, R.; Voysey, M.; Green, C.; Douglas, A. D.; Hill, A. V. S.; Lambe, T.; Gilbert, S. C.; Pollard, A. J.; Aboagye, J.; Adams, K.; Ali, A.; Allen, E.; Allison, J. L.; Anslow, R.; Arbe-Barnes, E. H.; Babbage, G.; Baillie, K.; Baker, M.; Baker, N.; Baker, P.; Baleanu, I.; Ballaminut, J.; Barnes, E.; Barrett, J.; Bates, L.; Batten, A.; Beadon, K.; Beckley, R.; Berrie, E.; Berry, L.; Beveridge, A.; Bewley, K. R.; Bijker, E. M.; Bingham, T.; Blackwell, L.; Blundell, C. L.; Bolam, E.; Boland, E.; Borthwick, N.; Bower, T.; Boyd, A.;

Brenner, T.; Bright, P. D.; Brown-O'Sullivan, C.; Brunt, E.; Burbage, J.; Burge, S.; Buttigieg, K. R.; Byard, N.; Cabera Puig, I.; Calvert, A.; Camara, S.; Cao, M.; Cappuccini, F.; Carr, M.; Carroll, M. W.; Carter, V.; Cathie, K.; Challis, R. J.; Charlton, S.; Chelysheva, I.; Cho, J.-S.; Cicconi, P.; Cifuentes, L.; Clark, H.; Clark, E.; Cole, T.; Colin-Jones, R.; Conlon, C. P.; Cook, A.; Coombes, N. S.; Cooper, R.; Cosgrove, C. A.; Coy, K.; Crocker, W. E. M.; Cunningham, C. J.; Damratoski, B. E.; Dando, L.; Datoo, M. S.; Davies, H.; De Graaf, H.; Demissie, T.; Di Maso, C.; Dietrich, I.; Dong, T.; Donnellan, F. R.; Douglas, N.; Downing, C.; Drake, J.; Drake-Brockman, R.; Drury, R. E.; Dunachie, S. J.; Edwards, N. J.; Edwards, F. D. L.; Edwards, C. J.; Elias, S. C.; Elmore, M. J.; Emary, K. R. W.; English, M. R.; Fagerbrink, S.; Felle, S.; Feng, S.; Field, S.; Fixmer, C.; Fletcher, C.; Ford, K. J.; Fowler, J.; Fox, P.; Francis, E.; Frater, J.; Furze, J.; Fuskova, M.; Galiza, E.; Gbesemete, D.; Gilbride, C.; Godwin, K.; Gorini, G.; Goulston, L.; Grabau, C.; Gracie, L.; Gray, Z.; Guthrie, L. B.; Hackett, M.; Halwe, S.; Hamilton, E.; Hamlyn, J.; Hanumunthadu, B.; Harding, I.; Harris, S. A.; Harris, A.; Harrison, D.; Harrison, C.; Hart, T. C.; Haskell, L.; Hawkins, S.; Head, I.; Henry, J. A.; Hill, J.; Hodgson, S. H. C.; Hou, M. M.; Howe, E.; Howell, N.; Hutlin, C.; Ikram, S.; Isitt, C.; Iveson, P.; Jackson, S.; Jackson, F.; James, S. W.; Jenkins, M.; Jones, E.; Jones, K.; Jones, C. E.; Jones, B.; Kailath, R.; Karampatsas, K.; Keen, J.; Kelly, S.; Kelly, D.; Kerr, D.; Kerridge, S.; Khan, L.; Khan, U.; Killen, A.; Kinch, J.; King, T. B.; King, L.; King, J.; Kingham-Page, L.; Klenerman, P.; Knapper, F.; Knight, J. C.; Knott, D.; Koleva, S.; Kupke, A.; Larkworthy, C. W.; Larwood, J. P. J.; Laskey, A.; Lawrie, A. M.; Lee, A.; Ngan Lee, K. Y.; Lees, E. A.; Legge, H.; Lelliott, A.; Lemm, N.-M.; Lias, A. M.; Linder, A.; Lipworth, S.; Liu, X.; Liu, S.; Lopez Ramon, R.; Lwin, M.; Mabesa, F.; Madhavan, M.; Mallett, G.; Mansatta, K.; Marcal, I.; Marinou, S.; Marlow, E.; Marshall, J. L.; Martin, J.; McEwan, J.; McInroy, L.; Meddaugh, G.; Mentzer, A. J.; Mirtorabi, N.; Moore, M.; Moran, E.; Morey, E.; Morgan, V.; Morris, S. J.; Morrison, H.; Morshead, G.; Morter, R.; Mujadidi, Y. F.; Muller, J.; Munera-Huertas, T.; Munro, C.; Munro, A.; Murphy, S.; Munster, V. J.; Mweu, P.; Noé, A.; Nugent, F. L.; Nuthall, E.; O'Brien, K.; O'Connor, D.; Oguti, B.; Oliver, J. L.; Oliveira, C.; O'Reilly, P. J.; Osborn, M.; Osborne, P.; Owen, C.; Owens, D.; Owino, N.; Pacurar, M.; Parker, K.; Parracho, H.; Patrick-Smith, M.; Payne, V.; Pearce, J.; Peng, Y.; Peralta Alvarez, M. P.; Perring, J.; Pfafferott, K.; Pipini, D.; Plested, E.; Pluess-Hall, H.; Pollock, K.; Poulton, I.; Presland, L.; Provstgaard-Morys, S.; Pulido, D.; Radia, K.; Ramos Lopez, F.; Rand, J.; Ratcliffe, H.; Rawlinson, T.; Rhead, S.; Riddell, A.; Ritchie, A. J.; Roberts, H.; Robson, J.; Roche, S.; Rohde, C.; Rollier, C. S.; Romani, R.; Rudiansyah, I.; Saich, S.; Sajjad, S.; Salvador, S.; Sanchez Riera, L.; Sanders, H.; Sanders, K.; Sapaun, S.; Sayce, C.; Schofield, E.; Screaton, G.; Selby, B.; Semple, C.; Sharpe, H. R.; Shaik, I.; Shea, A.; Shelton, H.; Silk, S.; Silva-Reyes, L.; Skelly, D. T.; Smee, H.; Smith, C. C.; Smith, D. J.; Song, R.; Spencer, A. J.; Stafford, E.; Steele, A.; Stefanova, E.; Stockdale, L.; Szigeti, A.; Tahiri-Alaoui, A.; Tait, M.; Talbot, H.; Tanner, R.; Taylor, I. J.; Taylor, V.; Te Water Naude, R.; Thakur, N.; Themistocleous, Y.; Themistocleous, A.; Thomas, M.; Thomas, T. M.; Thompson, A.; Thomson-Hill, S.; Tomlins, J.; Tonks, S.; Towner, J.; Tran, N.; Tree, J. A.; Truby, A.; Turkentine, K.; Turner, C.; Turner, N.; Turner, S.; Tuthill, T.; Ulaszewska, M.; Varughese, R.; Van Doremalen, N.; Veighey, K.; Verheul, M. K.; Vichos, I.; Vitale, E.; Walker, L.; Watson, M. E. E.; Welham, B.; Wheat, J.; White, C.; White, R.; Worth, A. T.; Wright, D.; Wright, S.; Yao, X. L.; Yau, Y., Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet* 2020, *396* (10249), 467-478.

99.   Bal, A.; Pozzetto, B.; Trabaud, M. A.; Escuret, V.; Rabilloud, M.; Langlois-Jacques, C.; Paul, A.; Guibert, N.; D'Aubarede-Frieh, C.; Massardier-Pilonchery, A.; Fabien, N.; Goncalves, D.; Boibieux, A.; Morfin-Sherpa, F.; Pitiot, V.; Gueyffier, F.; Lina, B.; Fassier, J. B.; Trouillet-Assant, S., Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of patients with mild COVID-19: clinical sensitivity, specificity and association with virus neutralization test. *Clinical chemistry* 2021.

100.   Wajnberg, A.; Amanat, F.; Firpo, A.; Altman, D. R.; Bailey, M. J.; Mansour, M.; McMahon, M.; Meade, P.; Mendu, D. R.; Muellers, K.; Stadlbauer, D.; Stone, K.; Strohmeier, S.; Simon, V.;

Aberg, J.; Reich, D. L.; Krammer, F.; Cordon-Cardo, C., Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *2020,* *370* (6521), 1227-1230.

101. Muruato, A. E.; Fontes-Garfias, C. R.; Ren, P.; Garcia-Blanco, M. A.; Menachery, V. D.; Xie, X.; Shi, P.-Y., A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. *Nature Communications* **2020,** *11* (1), 4059.

102. Tan, C. W.; Chia, W. N.; Qin, X.; Liu, P.; Chen, M. I. C.; Tiu, C.; Hu, Z.; Chen, V. C.-W.; Young, B. E.; Sia, W. R.; Tan, Y.-J.; Foo, R.; Yi, Y.; Lye, D. C.; Anderson, D. E.; Wang, L.-F., A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. *Nature Biotechnology* **2020,** *38* (9), 1073-1078.

103. Tang, M. S.; Case, J. B.; Franks, C. E.; Chen, R. E.; Anderson, N. W.; Henderson, J. P.; Diamond, M. S.; Gronowski, A. M.; Farnsworth, C. W., Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays. *Clinical chemistry* **2020**.

104. Suhandynata, R.; Hoffman, M.; Huang, D.; Tran, J.; Kelner, M.; Reed, S.; McLawhon, R.; Voss, J.; Nemazee, D.; Fitzgerald, R., Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2. medRxiv: 2020.

105. Patel, E. U.; Bloch, E. M.; Clarke, W.; Hsieh, Y.-H.; Boon, D.; Eby, Y.; Fernandez, R. E.; Baker, O. R.; Keruly, M.; Kirby, C. S.; Klock, E.; Littlefield, K.; Miller, J.; Schmidt, H. A.; Sullivan, P.; Piwowar-Manning, E.; Shrestha, R.; Redd, A. D.; Rothman, R. E.; Sullivan, D.; Shoham, S.; Casadevall, A.; Quinn, T. C.; Pekosz, A.; Tobian, A. A. R.; Laeyendecker, O., Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. *2020,* 2020.08.31.20184788.

106. Tsang, N. N. Y.; So, H. C.; Ng, K. Y.; Cowling, B. J.; Leung, G. M.; Ip, D. K. M., Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. *The Lancet Infectious Diseases*.

107. Sun, M.; Guo, D.; Zhang, J.; Zhang, J.; Teng, F.-H.; Xia, J.; Liu, P.; Ge, Q.-X.; Wang, M.-Y., Anal swab as a potentially optimal specimen for SARS-CoV-2 detection to evaluate hospital discharge of COVID-19 patients. *Future Microbiol* **2020,** *15,* 1101-1107.

108. Yurkovetskiy, L.; Wang, X.; Pascal, K. E.; Tomkins-Tinch, C.; Nyalile, T. P.; Wang, Y.; Baum, A.; Diehl, W. E.; Dauphin, A.; Carbone, C.; Veinotte, K.; Egri, S. B.; Schaffner, S. F.; Lemieux, J. E.; Munro, J. B.; Rafique, A.; Barve, A.; Sabeti, P. C.; Kyratsous, C. A.; Dudkina, N. V.; Shen, K.; Luban, J., Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. *Cell* **2020,** *183* (3), 739-751.e8.

109. Zhang, Y.; Xi, H.; Juhas, M., Biosensing Detection of the SARS-CoV-2 D614G Mutation. *Trends in Genetics* **2020**.

110. Zhang, L.; Guo, H., Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. *Advances in Biomarker Sciences and Technology* **2020,** *2,* 1-23.

111. Oberhaus, F. V.; Frense, D.; Beckmann, D., Immobilization Techniques for Aptamers on Gold Electrodes for the Electrochemical Detection of Proteins: A Review. *Biosensors* **2020,** *10* (5).

112. Li, K.; Gupta, R.; Drayton, A.; Barth, I.; Conteduca, D.; Reardon, C.; Dholakia, K.; Krauss, T. F., Extended Kalman Filtering Projection Method to Reduce the 3σ Noise Value of Optical Biosensors. *ACS Sensors* **2020,** *5* (11), 3474-3482.

113. Cui, Y.; Wei, Q.; Park, H.; Lieber, C. M., Nanowire Nanosensors for Highly Sensitive and Selective Detection of Biological and Chemical Species. *Science* **2001,** *293* (5533), 1289-1292.

114. Kong, J.; Franklin, N. R.; Zhou, C.; Chapline, M. G.; Peng, S.; Cho, K.; Dai, H., Nanotube Molecular Wires as Chemical Sensors. *Science* **2000,** *287* (5453), 622.

115. Patolsky, F.; Zheng, G.; Hayden, O.; Lakadamyali, M.; Zhuang, X.; Lieber, C. M., Electrical detection of single viruses. *Proceedings of the National Academy of Sciences of the United States of America* **2004,** *101* (39), 14017.

116. Shen, F.; Wang, J.; Xu, Z.; Wu, Y.; Chen, Q.; Li, X.; Jie, X.; Li, L.; Yao, M.; Guo, X.; Zhu, T., Rapid Flu Diagnosis Using Silicon Nanowire Sensor. *Nano Letters* **2012,** *12* (7), 3722-3730.

117.   Gongalsky, M. B.; Tsurikova, U. A.; Samsonova, J. V.; Gvindzhiliiia, G. Z.; Gonchar, K. A.; Saushkin, N. Y.; Kudryavtsev, A. A.; Kropotkina, E. A.; Gambaryan, A. S.; Osminkina, L. A., Double etched porous silicon nanowire arrays for impedance sensing of influenza viruses. *Results in Materials* **2020,** *6*.

118.   Xian, M.; Carey, P. H.; Fares, C.; Ren, F.; Shan, S. S.; Liao, Y. T.; Esquivel-Upshaw, J. F.; Pearton, S. J. In *Rapid Electrochemical Detection for SARS-CoV-2 and Cardiac Troponin I Using Low-Cost, Disposable and Modular Biosensor System*, 2020 IEEE Research and Applications of Photonics in Defense Conference (RAPID), 10-12 Aug. 2020; 2020; pp 1-2.

119.   Seo, G.; Lee, G.; Kim, M. J.; Baek, S. H.; Choi, M.; Ku, K. B.; Lee, C. S.; Jun, S.; Park, D.; Kim, H. G.; Kim, S. J.; Lee, J. O.; Kim, B. T.; Park, E. C.; Kim, S. I., Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor. *ACS Nano* **2020,** *14* (4), 5135-5142.

120.   Alafeef, M.; Dighe, K.; Moitra, P.; Pan, D., Rapid, Ultrasensitive, and Quantitative Detection of SARS-CoV-2 Using Antisense Oligonucleotides Directed Electrochemical Biosensor Chip. *ACS Nano* **2020**.

121.   Shariati, M.; Sadeghi, M., Ultrasensitive DNA biosensor for hepatitis B virus detection based on tin-doped WO3/In2O3 heterojunction nanowire electrode under laser amplification. *Anal Bioanal Chem* **2020,** *412* (22), 5367-5377.

122.   Ishikawa, F. N.; Chang, H.-K.; Curreli, M.; Liao, H.-I.; Olson, C. A.; Chen, P.-C.; Zhang, R.; Roberts, R. W.; Sun, R.; Cote, R. J.; Thompson, M. E.; Zhou, C., Label-Free, Electrical Detection of the SARS Virus N-Protein with Nanowire Biosensors Utilizing Antibody Mimics as Capture Probes. *ACS Nano* **2009,** *3* (5), 1219-1224.

123.   Owen, T. W.; Al-Kaysi, R. O.; Bardeen, C. J.; Cheng, Q., Microgravimetric immunosensor for direct detection of aerosolized influenza A virus particles. *Sensors and Actuators B: Chemical* **2007,** *126* (2), 691-699.

124.   Cooper, M. A.; Dultsev, F. N.; Minson, T.; Ostanin, V. P.; Abell, C.; Klenerman, D., Direct and sensitive detection of a human virus by rupture event scanning. *Nature Biotechnology* **2001,** *19* (9), 833-837.

125.   Shafiee, H.; Lidstone, E. A.; Jahangir, M.; Inci, F.; Hanhauser, E.; Henrich, T. J.; Kuritzkes, D. R.; Cunningham, B. T.; Demirci, U., Nanostructured optical photonic crystal biosensor for HIV viral load measurement. *Sci Rep* **2014,** *4*, 4116.

126.   Huang, L.; Ding, L.; Zhou, J.; Chen, S.; Chen, F.; Zhao, C.; Xu, J.; Hu, W.; Ji, J.; Xu, H.; Liu, G. L., One-step rapid quantification of SARS-CoV-2 virus particles via low-cost nanoplasmonic sensors in generic microplate reader and point-of-care device. *Biosens Bioelectron* **2021,** *171*, 112685.

127.   Wang, C.; Wang, C.; Wang, X.; Wang, K.; Zhu, Y.; Rong, Z.; Wang, W.; Xiao, R.; Wang, S., Magnetic SERS Strip for Sensitive and Simultaneous Detection of Respiratory Viruses. *ACS Appl Mater Interfaces* **2019,** *11* (21), 19495-19505.

128.   Vollmer, F.; Arnold, S.; Keng, D., Single virus detection from the reactive shift of a whispering-gallery mode. *Proceedings of the National Academy of Sciences* **2008,** *105* (52), 20701.

129.   Priye, A.; Bird, S. W.; Light, Y. K.; Ball, C. S.; Negrete, O. A.; Meagher, R. J., A smartphone-based diagnostic platform for rapid detection of Zika, chikungunya, and dengue viruses. *Scientific Reports* **2017,** *7* (1), 44778.

130.   Grantz, K. H.; Meredith, H. R.; Cummings, D. A. T.; Metcalf, C. J. E.; Grenfell, B. T.; Giles, J. R.; Mehta, S.; Solomon, S.; Labrique, A.; Kishore, N.; Buckee, C. O.; Wesolowski, A., The use of mobile phone data to inform analysis of COVID-19 pandemic epidemiology. *Nature Communications* **2020,** *11* (1), 4961.

131.   Bhalla, N.; Pan, Y.; Yang, Z.; Payam, A. F., Opportunities and Challenges for Biosensors and Nanoscale Analytical Tools for Pandemics: COVID-19. *ACS Nano* **2020,** *14* (7), 7783-7807.

132.   Wang, S.; Hossain, M. Z.; Han, T.; Shinozuka, K.; Suzuki, T.; Kuwana, A.; Kobayashi, H., Avidin-Biotin Technology in Gold Nanoparticle-Decorated Graphene Field Effect Transistors for

Detection of Biotinylated Macromolecules with Ultrahigh Sensitivity and Specificity. *ACS Omega* **2020,** *5* (46), 30037-30046.

133. Baaske, M. D.; Foreman, M. R.; Vollmer, F., Single-molecule nucleic acid interactions monitored on a label-free microcavity biosensor platform. *Nature Nanotechnology* **2014,** *9* (11), 933-939.

134. Huang, J. C.; Chang, Y. F.; Chen, K. H.; Su, L. C.; Lee, C. W.; Chen, C. C.; Chen, Y. M.; Chou, C., Detection of severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in human serum using a localized surface plasmon coupled fluorescence fiber-optic biosensor. *Biosens Bioelectron* **2009,** *25* (2), 320-325.

135. Shanmukh, S.; Jones, L.; Driskell, J.; Zhao, Y.; Dluhy, R.; Tripp, R. A., Rapid and Sensitive Detection of Respiratory Virus Molecular Signatures Using a Silver Nanorod Array SERS Substrate. *Nano Lett* **2006,** *6* (11), 2630-2636.

136. Dantham, V. R.; Holler, S.; Kolchenko, V.; Wan, Z.; Arnold, S., Taking whispering gallery mode single virus detection and sizing to the limit. *Applied Physics Letters* **2012,** *101* (4), 043704.

137. Vincent, S.; Subramanian, S.; Vollmer, F., Optoplasmonic characterisation of reversible disulfide interactions at single thiol sites in the attomolar regime. *Nature Communications* **2020,** *11* (1), 2043.

138. To, K. K.-W.; Tsang, O. T.-Y.; Leung, W.-S.; Tam, A. R.; Wu, T.-C.; Lung, D. C.; Yip, C. C.-Y.; Cai, J.-P.; Chan, J. M.-C.; Chik, T. S.-H.; Lau, D. P.-L.; Choi, C. Y.-C.; Chen, L.-L.; Chan, W.-M.; Chan, K.-H.; Ip, J. D.; Ng, A. C.-K.; Poon, R. W.-S.; Luo, C.-T.; Cheng, V. C.-C.; Chan, J F.-W.; Hung, I. F.-N.; Chen, Z.; Chen, H.; Yuen, K.-Y., Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases* **2020,** *20* (5), 565-574.

139. Schmidt, H.; Hawkins, A. R., Single-virus analysis through chip-based optical detection. *Bioanalysis* **2016,** *8* (9), 867-870.

140. Guo, Z.; Lu, Q.; Zhu, C.; Wang, B.; Zhou, Y.; Wu, X., Ultrasensitive biomolecular detection by external referencing optofluidic microbubble resonator. *Opt Express* **2019,** *27* (9), 12424-12435.

141. Sakamoto, H.; Minpou, Y.; Sawai, T.; Enami, Y.; Suye, S., A Novel Optical Biosensing System Using Mach-Zehnder-Type Optical Waveguide for Influenza Virus Detection. *Appl Biochem Biotechnol* **2016,** *178* (4), 687-694.

142. Sai, V. V.; Kundu, T.; Mukherji, S., Novel U-bent fiber optic probe for localized surface plasmon resonance based biosensor. *Biosens Bioelectron* **2009,** *24* (9), 2804-2809.

143. Bandaru, R.; Divagar, M.; Khanna, S.; Danny, C. G.; Gupta, S.; Janakiraman, V.; V V R, S., U-bent fiber optic plasmonic biosensor platform for ultrasensitive analyte detection. *Sensors and Actuators B: Chemical* **2020,** *321*, 128463.

144. Murugan, D.; Bhatia, H.; Sai, V. V. R.; Satija, J., P-FAB: A Fiber-Optic Biosensor Device for Rapid Detection of COVID-19. *Transactions of the Indian National Academy of Engineering* **2020,** *5* (2), 211-215.

145. Xiao, R.; Lu, L.; Rong, Z.; Wang, C.; Peng, Y.; Wang, F.; Wang, J.; Sun, M.; Dong, J.; Wang, D.; Wang, L.; Sun, N.; Wang, S., Portable and multiplexed lateral flow immunoassay reader based on SERS for highly sensitive point-of-care testing. *Biosens Bioelectron* **2020,** *168*, 112524.

146. Jadhav, S. A.; Biji, P.; Panthalingal, M. K.; Murali Krishna, C.; Rajkumar, S.; Joshi, D. S.; Sundaram, N., Development of integrated microfluidic platform coupled with Surface-enhanced Raman Spectroscopy for diagnosis of COVID-19. *Medical Hypotheses* **2021,** *146*, 110356.

147. Pal, S.; Yadav, A. R.; Lifson, M. A.; Baker, J. E.; Fauchet, P. M.; Miller, B. L., Selective virus detection in complex sample matrices with photonic crystal optical cavities. *Biosens Bioelectron* **2013,** *44*, 229-234.

148. Yanik, A. A.; Huang, M.; Kamohara, O.; Artar, A.; Geisbert, T. W.; Connor, J. H.; Altug, H., An optofluidic nanoplasmonic biosensor for direct detection of live viruses from biological media. *Nano Lett* **2010,** *10* (12), 4962-4969.

149.   Lakadamyali, M.; Rust, M. J.; Babcock, H. P.; Zhuang, X., Visualizing infection of individual influenza viruses. *Proceedings of the National Academy of Sciences of the United States of America* **2003,** *100* (16), 9280-9285.

150.   Scherr, S. M.; Daaboul, G. G.; Trueb, J.; Sevenler, D.; Fawcett, H.; Goldberg, B.; Connor, J. H.; Unlu, M. S., Real-Time Capture and Visualization of Individual Viruses in Complex Media. *ACS Nano* **2016,** *10* (2), 2827-33.

151.   Zhao, B.; Che, C.; Wang, W.; Li, N.; Cunningham, B. T., Single-step, wash-free digital immunoassay for rapid quantitative analysis of serological antibody against SARS-CoV-2 by photonic resonator absorption microscopy. *Talanta* **2021,** *225*, 122004.

152.   Torrente-Rodriguez, R. M.; Lukas, H.; Tu, J.; Min, J.; Yang, Y.; Xu, C.; Rossiter, H. B.; Gao, W., SARS-CoV-2 RapidPlex: A Graphene-Based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and Monitoring. *Matter* **2020,** *3* (6), 1981-1998.

153.   Shan, B.; Broza, Y. Y.; Li, W.; Wang, Y.; Wu, S.; Liu, Z.; Wang, J.; Gui, S.; Wang, L.; Zhang, Z.; Liu, W.; Zhou, S.; Jin, W.; Zhang, Q.; Hu, D.; Lin, L.; Zhang, Q.; Li, W.; Wang, J.; Liu, H.; Pan, Y.; Haick, H., Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath. *ACS Nano* **2020,** *14* (9), 12125-12132.

154.   Pandey, L. M., Design of engineered surfaces for prospective detection of SARS-CoV-2 using quartz crystal microbalance-based techniques. *Expert Rev Proteomic* **2020,** *17* (6), 425-432.

155.   Shi, L.; Sun, Q.; He, J.; Xu, H.; Liu, C.; Zhao, C.; Xu, Y.; Wu, C.; Xiang, J.; Gu, D.; Long, J.; Lan, H., Development of SPR biosensor for simultaneous detection of multiplex respiratory viruses. *Biomed Mater Eng* **2015,** *26 Suppl 1*, S2207-S2216.

156.   Yoo, H.; Shin, J.; Sim, J.; Cho, H.; Hong, S., Reusable surface plasmon resonance biosensor chip for the detection of H1N1 influenza virus. *Biosens Bioelectron* **2020,** *168*, 112561.

157.   Lim, R. R. X.; Bonanni, A., The potential of electrochemistry for the detection of coronavirus-induced infections. *Trends Analyt Chem* **2020,** *133*, 116081.

158.   Flower, B.; Brown, J. C.; Simmons, B.; Moshe, M.; Frise, R.; Penn, R.; Kugathasan, R.; Petersen, C.; Daunt, A.; Ashby, D.; Riley, S.; Atchison, C. J.; Taylor, G. P.; Satkunarajah, S.; Naar, L.; Klaber, R.; Badhan, A.; Rosadas, C.; Khan, M.; Fernandez, N.; Sureda-Vives, M.; Cheeseman, H. M.; Hara, J.; Fontana, G.; Pallett, S. J. C.; Rayment, M.; Jones, R.; Moore, L. S. P.; McClure, M.; O.; Cherepanov, P.; Tedder, R.; Ashrafian, H.; Shattock, R.; Ward, H.; Darzi, A.; Elliot, P.; Barclay, W. S.; Cooke, G. S., Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. *Thorax* **2020,** *75* (12), 1082.

Table of Contents